

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 473/00, C07C 217/52 C07D 221/22, A61K 31/52	A2	(11) International Publication Number: WO 93/17020 (43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/GB93/00378 (22) International Filing Date: 24 February 1993 (24.02.93) (30) Priority data: 9204015.3 25 February 1992 (25.02.92) GB (71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : DALUGE, Susan, Mary [US/US]; 297 Azalea Drive, Chapel Hill, NC 27514 (US). LIVINGSTON, Douglas, Alan [US/US]; LaJolla Pharmaceutical Co., 6455 Nancy Ridge Drive, San Diego, CA 92121 (US).		(74) Agent: GARRETT, Michael; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: THERAPEUTIC NUCLEOSIDES (57) Abstract The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain viral infections.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Therapeutic Nucleosides

The present invention relates to purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, pharmaceutically acceptable derivatives thereof, and their use in medical therapy, particularly for the treatment of certain viral infections.

Hepatitis B virus (HBV) is a small DNA containing virus which infects humans. It is a member of the class of closely related viruses known as the hepadnaviruses, each member of which selectively infects either mammalian or avian hosts, such as the woodchuck and the duck.

Worldwide, HBV is a viral pathogen of major consequence. It is most common in Asian countries, and prevalent in sub-Saharan Africa. The virus is etiologically associated with primary hepatocellular carcinoma and is thought to cause 80% of the world's liver cancer. In the United States more than ten thousand people are hospitalized for HBV illness each year, an average of 250 die with fulminant disease.

The United States currently contains an estimated pool of 500,000-1 million infectious carriers. Chronic active hepatitis will develop in over 25% of carriers, and often progresses to cirrhosis. It is estimated that 5000 people die from HBV-related cirrhosis each year in the USA, and that perhaps 1000 die from HBV-related liver cancer. Even when a universal HBV vaccine is in place, the need for effective anti-HBV compounds will continue. The large reservoir of persistently infected carriers, estimated at 220 million worldwide, will receive no benefit from vaccination and will continue at high risk for HBV-induced liver disease. This carrier population serves as the source of infection of susceptible individuals perpetuating the instance of disease particularly in endemic areas or high risk groups such as IV drug abusers and homosexuals. Thus, there is a great need for effective antiviral agents, both to control the chronic infection and reduce progression to hepatocellular carcinoma.

Clinical effects of infection with HBV range from headache, fever, malaise, nausea, vomiting, anorexia and abdominal pains. Replication of the virus is usually controlled by the immune response, with a course of recovery lasting weeks or months in humans, but infection may be more severe leading to persistent chronic liver disease as outlined above. In "Viral Infections of Humans" (second edition, Ed., Evans, A.S. (1982) Plenum Publishing Corporation, New York), Chapter 12 describes in detail the etiology of viral hepatitis infections.

Of the DNA viruses, the herpes group is the source of many common viral illnesses in man. The group includes cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), herpes simplex virus (HSV) and human herpes virus 6 (HHV6).

In common with other herpes viruses, infection with CMV leads to a life-long association of virus and host and, following a primary infection, virus may be shed for a number of years. Clinical effects range from death and gross disease (microcephaly, hepatosplenomegaly, jaundice, mental retardation) through failure to thrive, susceptibility to chest and ear infections to a lack of any obvious ill effect. CMV infection in AIDS patients is a predominant cause of morbidity as, in 40 to 80% of the adult population, it is present in a latent form and can be reactivated in immunocompromised patients.


EBV causes infectious mononucleosis and is also suggested as the causative agent of nasopharyngeal cancer, immunoblastic lymphoma, Burkitt's lymphoma and hairy leukoplakia.

VZV causes chicken pox and shingles. Chicken pox is the primary disease produced in a host without immunity. In young children, it is usually a mild illness characterized by a vesicular rash and fever. Shingles is the recurrent form of the disease which occurs in adults who were previously infected with varicella. The clinical manifestations of shingles include neuralgia and a vesicular skin rash that is unilateral and dermatomal in distribution. Spread of inflammation may lead to paralysis or convulsions and coma can occur if the meninges becomes affected. In immunodeficient patients, VZV may disseminate causing serious or even fatal illness.

HSV 1 and HSV 2 are some of the most common infectious agents of man. Most of these viruses are able to persist in the host's neural cells. Once infected, individuals are at risk of recurrent clinical manifestation of infection which can be both physically and psychologically distressing. HSV infection is often characterized by extensive lesions of the skin, mouth and/or genitals. Primary infections may be subclinical although they tend to be more severe than infections in individuals previously exposed to the virus. Ocular infections by HSV can lead to keratitis or cataracts. Infection in the newborn, in immunocompromised patients or penetration of infection into the central nervous system can prove fatal. HHV6 is the causative agent of roseola infantum (exanthum subitum) in children which is characterized by fever and the appearance of a rash after the fever has declined. HHV6 has also been implicated in syndromes of fever and/or rash and pneumonia or hepatitis in immunocompromised patients.

It has been reported that the carbocyclic analogue of 2'-deoxyguanosine (2'-CDG) i.e. (1R*,3S*,4R*)-2-amino-1,9-dihydro-9-[3-hydroxy-4-(hydroxymethyl)cyclopentyl]-6H-purine-6-one, is active against several viruses. Thus in Proc. Natl. Acad. Sci. USA 1989, Vol. 86, pp8541-8544, it is disclosed that 2'-CDG inhibits hepatitis B viral replication. J. Med.Chem (1987) 30, pp746-749 and Biochemical Pharmacology (1990) Vol. 40, No. 7, pp1515-1522, report 2'-CDG, especially the (+)-enantiomer, as active against herpes simplex virus type 1 (HSV-1). Furthermore 2'-CDG and general analogues thereof are disclosed together with a plurality of other compounds in the following patent publications: U.S.4,543,255 (with reference to HSV1 and 2), PCT 90/06671 (with reference to hepatitis B), EP 219838, PCT 91/13549 (with reference to cytomegalovirus (CMV)). Other publication relating to 2'-CDG and the preparation thereof are J.Med. Chem. (1984) 27, pp1416-1421, and J.Chem.Soc.Chem. Commun. (1987) pp1083-1084.

It has now been discovered that certain analogues of 2'-CDG as referred to below, are useful for the treatment or prophylaxis of certain viral infections. According to a first aspect of the present invention, novel compounds of the formula (I) are provided:



wherein R¹ represents

hydrogen;

C₃₋₈ alkenyloxy; C₃₋₈ cycloalkoxy (e.g. cyclopentoxy); C₄₋₈ cycloalkenyloxy (e.g. cyclopenten-3-yloxy); aryloxy (e.g. phenoxy) or arylalkoxy (e.g. benzyloxy) in which the aryl may be substituted with one or more C₁₋₄ alkyl, halogen, hydroxy, C₁₋₄ alkoxy, amino or nitro;

C₃₋₆ alkenylthio (e.g. allylthio); C₃₋₆ cycloalkylthio; C₄₋₈ cycloalkenylthio; arylthio (e.g. phenylthio) or arylalkylthio (e.g. benzylthio) in which the aryl may be substituted with one or more C₁₋₄ alkyl, halogen, hydroxy, C₁₋₄ alkoxy, amino or nitro;

an amino group, -NR²R³, in which R² and R³ may be the same or different and are independently selected from hydrogen; C₁₋₈ alkyl; C₁₋₆ alkoxy; C₁₋₆ hydroxyalkyl (e.g. hydroxyethyl); C₁₋₆ alkoxyalkyl (e.g. methoxyethyl); C₃₋₇ cycloalkyl (e.g. cyclopropyl, cyclobutyl or cyclopentyl) in which the cycloalkyl may be substituted by one or more C₁₋₆ alkyl or hydroxy; aryl (e.g. phenyl) or aralkyl (e.g. benzyl) in which the aryl may be substituted with one or more C₁₋₄ alkyl, halogen, hydroxy, C₁₋₄ alkoxy, amino or nitro; C₃₋₆ alkenyl (e.g. allyl); or R² and R³ together form a 4- to 8-membered ring (e.g. azetidiny or pyrrolidiny); provided that R² and R³ cannot both be hydrogen or both be C₁₋₈ alkyl;

4-morpholinyl, 1-piperazinyl or 1-pyrrollyl;

or a pharmaceutically acceptable derivative thereof.

It is to be understood that the present invention encompasses the particular enantiomers depicted in formula (I), including tautomers of the purine, alone and in combination with their mirror-image enantiomers which are not depicted. Enantiomers depicted by formula (I), the "relevant" enantiomers, are preferred and more preferably the relevant enantiomer is provided substantially free of the corresponding enantiomer to the extent that it is generally in admixture with less than 10% w/w, preferably less than 5% w/w, more preferably less than 2% w/w and most preferably less than 1% w/w of the corresponding enantiomer based on the total weight of the mixture.

However, the processes disclosed pertain to the preparation opposite enantiomers via Examples 11-17 and Example 34.

Where reference herein is made to an alkyl moiety, this includes methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl and hexyl.

Furthermore reference to C₃₋₇ cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

Preferably R¹ represents a C₃₋₇ cycloalkylamino most preferably cyclopropyl.

Particularly preferred examples of compounds of formula (I), exhibiting decreased toxicity compared to 2'-CDG, are:

- a) (+)-(1S,2R,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol
- b) (+)-(1S,2R,4S)-4-(2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol
- c) (+)-(1S,2R,4R)-4-(2-amino-6-(1-pyrrolidinyl)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol
- d) (+)-(1S,2R,4R)-4-[6-(allylthio)-2-amino-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol
- e) (+)-(1S,2R,4R)-4-(2-amino-6-(cyclopentyloxy)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol
- f) (+)-(1S,2R,4R)-4-(2-amino-6-(1-azetidiny)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol

and pharmaceutically acceptable salts thereof.

The compounds of formula (I) above and their pharmaceutically acceptable derivatives are herein referred to as the compounds according to the invention.

In a further aspect of the invention there are provided the compounds according to the invention for use in medical therapy particularly for the treatment or prophylaxis of viral infections such as hepadnaviral infections and herpes viral infections. To date compounds of the invention has been shown to be active against hepatitis B virus (HBV) and cytomegalovirus (CMV) infections, although early results also suggest that the invention could also be active against other herpes virus infections such as EBV, VZV, HSVI and II and HHV6.

Other viral conditions which may be treated in accordance with the invention have been discussed in the introduction hereinbefore.

In yet a further aspect of the present invention there is provided:

- a) A method for the treatment or prophylaxis of a hepadnaviral infection such as hepatitis B or a herpes viral infection such as CMV which comprises treating the subject with a therapeutically effective amount of a compound according to the invention.
- b) Use of a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of any of the above-mentioned infections or conditions.

By "a pharmaceutically acceptable derivative" is meant any pharmaceutically or pharmacologically acceptable salt, ester or salt of such ester of a compound according to the invention, or any compound which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound according to the invention, or an antivirally active metabolite or residue thereof.

Preferred esters of the compounds of the invention include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain alkyl, e.g. n-propyl, t-butyl, n-butyl, alkoxyalkyl (e.g. methoxymethyl), aralkyl (e.g. benzyl), aryloxyalkyl (e.g. phenoxymethyl), aryl (e.g. phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy or amino); sulfonate esters such as alkyl- or aralkylsulfonyl (e.g. methanesulfonyl); amino acid esters (e.g. L-valyl or L-isoleucyl); and mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C₁₋₂₀ alcohol or reactive derivative thereof, or by a 2,3-di(C₆₋₂₄)acyl glycerol.

With regard to the above-described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 18 carbon atoms, particularly 3 to 6 carbon atoms such as the pentanoate. Any aryl moiety present in such esters advantageously comprises a phenyl group.

Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof.

Pharmaceutically acceptable salts include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic, p-aminobenzoic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.

The above compounds according to the invention and their pharmaceutically acceptable derivatives may be employed in combination with other therapeutic agents for the treatment of the above infections or conditions. Examples of such further therapeutic agents include agents that are effective for the treatment of viral infections or associated conditions such as acyclic nucleosides (e.g. acyclovir), immunomodulatory agents such as thymosin, ribonucleotide reductase inhibitors such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl]thiocarbonohydrazide, interferons such as α -interferon, 1- β -D-arabinofuranosyl-5-(1-propynyl)uracil, 3'-azido-3'-deoxythymidine, ribavirin and phosphonoformic acid. The component compounds of such combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times, e.g. sequentially such that a combined effect is achieved.

The compounds according to the invention, also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the infection and the chosen active ingredient.

In general a suitable dose for each of the above-mentioned conditions will be in the range of 0.01 to 250 mg per kilogram body weight of the recipient (e.g. a human) per day, preferably in the range of 0.1 to 100 mg per kilogram body weight per day and most preferably in the range 1.0 to 20 mg per kilogram body weight per day. (Unless otherwise indicated, all weights of active ingredient are calculated as the parent compound of formula (I); for salts or esters thereof, the weights would be increased proportionally.) The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1000 mg, preferably 20 to 500 mg, and most preferably 100 to 400 mg of active ingredient per unit dosage form.

Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.025 to about 100 μ M, preferably about 0.1 to 70 μ M, most preferably about 0.25 to 50 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 0.1 to about 250 mg/kg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide

about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

While it is possible for the active ingredient to be administered alone it is preferable to present it as a pharmaceutical formulation. The formulations of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical (including transdermal buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 25%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis as generally described in Pharmaceutical Research, 3 (6), 318 (1986).

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent,

preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.


Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multidose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having


regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.

The present invention further includes the following process for the preparation of compounds of formula (I) above and derivatives thereof either alone or in combination with their corresponding enantiomers. The process according to the present invention comprises treating a compound of formula (Ia) either alone or in combination with its enantiomer (wherein Z represents a precursor group for the said R¹ group, R¹ defined as in formula (I)).




The conversion of (Ia) to (I) may be carried out in a conventional manner, for example, by treatment of a compound of formula (Ia) in which Z represents a leaving group (e.g. a halo, such as a chloro group) with an appropriate amine (e.g. methylamine or dimethylamine) or an appropriate alkoxide (e.g. sodium methoxide or potassium n-butoxide) or an appropriate alkylsulfide (e.g. sodium methylmercaptide) or with sodium hydrogen sulfide or thiourea to provide the 6-thiopurine (R¹ = mercapto) which is then alkylated with appropriate alkylating agents (e.g. n-propyl iodide, allyl chloride, and dimethyl sulfate) in the presence of an equivalent of base (e.g. sodium hydroxide or potassium t-butoxide) to provide the corresponding alkylthio compounds of formula (I).

The compounds of formula (Ia) employed as starting materials in the above process may be prepared by reacting a compound of formula (II) either alone or in combination with its enantiomer (wherein Z is defined as in formula (Ia) and R⁴ and R⁵ are either the same or different and may be either hydrogen, formyl, or an amino protecting group such as a C₂₋₆ alkanoyl, e.g. acetyl or isobutyryl, or C₁₋₆ alkoxy carbonyl, e.g. tert-butoxycarbonyl) with a reactive derivative of formic acid (e.g. triethylorthoformate or diethoxymethyl acetate) optionally with a cosolvent such as dimethylacetamide or dimethylformamide.



It is understood that when R^5 is other than hydrogen or formyl, deprotection preferably by prior treatment with dilute aqueous mineral acid is required prior to treatment with a reactive derivative of formic acid. In these cases the resulting mineral acid salt of (II) with R^4 and R^5 being hydrogen is efficiently converted directly to compounds of formula (Ia) by treatment with derivatives of formic acid, e.g. triethylorthoformate, preferably at 25°C for several hours. When other compounds of formula (II) are reacted with derivatives of formic acid, the reaction is conveniently effected by the addition of slightly more than one equivalent of a strong anhydrous acid, e.g. with 1.1 equivalents of ethanesulfonic acid per equivalent of (II) or 4 equivalents of concentrated aqueous hydrochloric acid per equivalent of (II), preferably at 25°C. It is understood that subsequent treatment of the resulting products with dilute aqueous acid, e.g. 1N hydrochloric acid at 25°C for several hours cleaves derivatives formed, for example, by reaction of the hydroxy groups with triethylorthoformate.

The compounds of formula (II) employed as starting materials in the above process may be prepared by reacting a compound of formula (IIIa) either alone or in combination with its enantiomer with an appropriately substituted pyrimidine, e.g. 2,5-diamino-4,6-dichloropyrimidine or preferably derivatives thereof, e.g., N-(4,6-dichloro-5-formamido-2-pyrimidinyl) isobutyramide as described in EP 434450, June 26, 1991. This reaction is preferably carried out at 80-120°C, e.g. at reflux in n-butanol or t-butanol with 1-2 equivalents of a base, e.g. triethylamine or potassium carbonate, for 1 to 3 hours.




(IIIa) $R^6 = H$

(IIIb) $R^6 =$ a protecting group as defined below

The compounds of formula (IIIa), either alone or in combination with their enantiomers, employed as starting materials as described above may be prepared for example by deprotection of protected compounds of formula (IIIb) by methods known in the art (T.W. Greene, "Protective Groups in Organic Synthesis," Wiley, New York, 1981, pp 218-287; J.F.W. McOmie, "Protective Groups in Organic Chemistry," Plenum Press, New York, 1973, pp. 43-93)

Most preferably, when R^6 = tert-butoxycarbonyl (BOC), deprotection can be achieved by the reaction with an acid of pK_a less than three as is known in the art and is exemplified below. The amino diol of structure (IIIa) is so obtained in the form of its salt, which is suitable for use in the reaction to prepare compounds of formula (I). The free base of the amino diol (IIIa) is obtained, for example, by contacting the salt with a quaternary ammonium-type anion exchange resin in its hydroxide form as is exemplified below.

The compounds of formula (IIIb) employed as starting materials as described above may be prepared for example by desilylation of protected compounds of formula (IVa) by reaction with fluoride ion, as is known in the art and exemplified below (T.W. Greene, "Protective Groups in Organic Synthesis," Wiley, New York, 1981, pp 218-287; J.F.W. McOmie, "Protective Groups in Organic Chemistry," Plenum Press, New York, 1973, pp. 43-93; W.T. Markiewicz, *Tetrahedron Letters* 1980, 21, 4523-4524); W.T. Markiewicz and M. Wiewiorowski, *Nucleic Acids Research Special Publication No. 4*, 3185-3188; W.T. Markiewicz, *J. Chem. Research (S)* 1979, 24-25; C.H.M. Verdegaal, P.L. Jansse, J.F.M. deRoos, G. Veeneman and J.H. vanBoom, *Recueil* 1981, 100, 200-204; C. Gioeli, M. Kwiatkowski, B. Oberg and J.B. Chattopadhyaya, *Tetrahedron Letters* 1981, 22, 1741-1744).





(IVa) Y = H
 (IVb) Y = OCSOPh
 (IVc) Y = OH

R^6 = a protecting group as defined below

It is surprising in view of the prior art that substantially less than two equivalents of fluoride ion is sufficient to effect deprotection. In the present case, approximately one equivalent of tetraethylammonium fluoride was found to be sufficient.

The compounds of formula (IVa) employed as starting materials as described above may be prepared for example by first thiocarbonation of the compounds of formula (IVc) to prepare thiocarbonates of formula (IVb), then reduction of the thiocarbonates of formula (IVb) with e.g. tributyltin hydride as is known in the art (M.J. Robins and J.S. Wilson, *J. Am. Chem. Soc.* **1981**, 103, 932-933; M.J. Robins, J.S. Wilson and F. Hansske, *J. Am. Chem. Soc.* **1985**, 105, 4059-4065; W. Hartwig, *Tetrahedron* **1983**, 39, 2609-2645 and references therein; D.H.R. Barton, D. Crich, A. Löbberding and S.Z. Zard, *Tetrahedron* **1986**, 42, 2329-2338; D.H.R. Barton and S.W. McCombie, *J. Chem. Soc., Perkin I* **1975**, 1574-1585; D.H.R. Barton, W.B. Motherwell and A. Stange, *Synthesis* **1981**, 743-745; N. Katagiri, M. Nomura, M. Muto and C. Kaneko, *Chem. Pharm. Bull.* **1991**, 39, 1682-1688) and is exemplified below.


The compounds of formula (IVc) employed as starting materials as described above may be prepared for example by selective protection through reaction of compounds of formula (V) with 1,3-dichloro-1,1,3,3-tetraisopropyl disiloxane as is known in the art (W.T. Markiewicz, N.S. Padyukova, Z. Samek, J. Smrt, *Collection Czechoslov. Chem. Commun.* **1980**, 45, 1860-1865; W.T. Markiewicz, *Tetrahedron Letters* **1980**, 21, 4523-4524; W.T. Markiewicz and M. Wiewiorowski, *Nucleic Acids Research Special Publication No. 4*, 3185-3188; W.T. Markiewicz, *J. Chem. Research (S)* **1979**, 24-25; C.H.M. Verdegaal, P.L. Jansse, J.F.M. deRoos, G. Veeneman and J.H. vanBoom, *Recueil* **1981**, 100, 200-204; C. Gioeli, M. Kwiatkowski, B. Oberg and J.B. Chattopadhyaya, *Tetrahedron Letters* **1981**, 22, 1741-1744) and is exemplified below.



R^6 = a protecting group as defined below

The compounds of formula (V) employed as starting materials as described above may be prepared for example by cis-dihydroxylation of compounds of structure (VIIa) using a catalytic amount of osmium tetroxide and N-methyl morpholine-N-oxide as is known in the art (V. VanRheenen, R.C. Kelly and D.Y. Cha, *Tetrahedron Letters* **1976**, 1973-1976; M. Schröder, *Chem. Rev.* **1980**, 80, 187-213). The cis-hydroxylation reaction results in a mixture of two geometrical isomers of structure (VI) and (V). The separation of these isomers can be

achieved by conventional methods such as chromatography or selective crystallization. The isomers wherein R^6 is BOC are most easily separated by crystallization, as is exemplified below.



(VIIa) R^6 = a protecting group as defined below


(VIIb) R^6 = H

The compounds of formula (VIIa) employed as starting materials as described above may be prepared for example by protection of the compound of formula (VIIb) by methods known in the art (T.W. Greene, "Protective Groups in Organic Synthesis," Wiley, New York, 1981, pp. 218-287; J.F.W. McOmie, "Protective Groups in Organic Chemistry," Plenum Press, New York, 1973, pp. 43-93). Preferred are R^6 = C_{2-6} alkanoyl (e.g. acetyl) and C_{2-6} alkyloxycarbonyl (e.g. tert-butoxy carbonyl, BOC). Most preferred is R^6 = BOC, which is exemplified below.

The resolved (-)-amino alcohol of formula (VIIb) or a protected derivative (VIIa) can now be used to synthesize resolved carbocyclic nucleosides, (e.g. (1S, 4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol) as illustrated in EP 434450 (US 5,087,697) and in the examples hereinafter. Thus, an enantiomer of a carbocyclic nucleoside is obtainable by applying reactions that form the corresponding pyrimidine or purine base of the desired nucleoside, as is known in the art and illustrated herein.

It will be appreciated that the steps from formation of the resolved (-)-amino alcohol of formula (VIIb) up to formation of (1S, 4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol as described in EP 434450 (US 5,087,697) are incorporated herein by reference, in particular Examples 1-5, 15-19, 26-28 and described herein (Examples 30-33).

Another aspect of the present invention includes a process for the preparation of (-)-(1S,4R)-4-amino-2-cyclopentene-1-methanol, compound (VIIb), its mirror image enantiomer and mixtures of such enantiomers. Each mirror image enantiomer can be used to prepare in conventional manner antiviral carbocyclic nucleosides of the corresponding enantiomeric configuration, for example as described in Molec. Pharm. 37, 395-401 (1990) and J. Med. Chem. 30, 746-749 (1987). This process comprises reducing (-)-(2S,4R)-4-amino-2-cyclopentene-1-carboxylic acid, compound (VIII), the mirror image enantiomer thereof or a mixture of such enantiomers.



It is preferred that compound (VIII) or its mirror image enantiomer be in the form of a salt, (VIIIa) or (VIIIb). Subsequent references to (VIII), (VIIIa) and (VIIIb) also include the mirror image enantiomers thereof and mixtures of the corresponding enantiomers. Suitable salts (VIIIa) include the lithium, sodium, potassium, magnesium or calcium salts. Most preferred is the sodium salt ($\text{W} = \text{Na}$ in structure (VIIIa)). Suitable salts (VIIIb) are those wherein the conjugate acid (XH) of the salt possesses a pK_a less than two. Suitable salts (VIIIb) thus include the hydrochloride, sulphate, bisulphate, hydrobromide, or organic sulphonic acid salt.


It is further preferred that the salt (VIIIb) be an organic sulphonic acid salt. It is most preferred that the organic sulphonic acid salt is a C_{1-6} alkyl sulphonic acid salt (e.g. methanesulphonyl) or aryl sulphonic acid salt (e.g. toluenesulphonyl). In structure (VIIIb), X would thus represent most preferably e.g. a methanesulphonate or toluenesulphonate group, respectively.

The present invention also includes the novel compounds of formulas (VIIIa) and (VIIIb) generically and specifically referred to above.

The reducing agent for conversion of (VIII), (VIIIa), or (VIIIb) to (VIIb) or for conversion of the respective mirror image enantiomers is preferably an aluminum hydride, such as diisobutyl aluminum hydride, sodium bis (2-methoxyethoxy)aluminum hydride, lithium aluminum hydride, sodium aluminum hydride, lithium tri-tert-butoxyaluminumhydride, etc. Most preferred is lithium aluminum hydride (D.A. Dickman, A.I. Meyers, G.A. Smith and R.E. Cawley, *Org. Syn. Coll. Vol VII*, 530-533). Advantageously a source of fluoride ion such as NaF (H. Yamamoto and K. Maruoka, *J. Org. Chem.* 1981, **103**, 4186-4194) is also used to help release the product from contaminating aluminum following the reduction reaction. Triethanolamine (J. Powell, N. James and S.J. Smith, *Synthesis*, 1986, 338-340) can be used in place of fluoride, but is less preferred.

The solvent for the reduction reaction is preferably an ether such as THF. It is further preferred that water (1-15% w/w) be added to the ether prior to isolation of the product, in order to increase the solubility of (VIIb).

In yet a further aspect of the invention there is provided a method of preparing compound (VIIIb), its mirror image enantiomer or a mixture of such enantiomers, comprising reacting (-)-2-azabicyclo[2.2.1]hept-5-en-3-one (IX), its mirror image enantiomer or a mixture of such enantiomers, with one or more equivalents of an acid and one or more equivalents of water. Preferred acids are those with pKa less than two, most preferred are acids that give directly the salts (VIIIb) described above, e.g. including methanesulphonic acid and toluenesulphonic acid.



(IX)

The reaction temperature can vary between 10°C and 120°C, but is most preferably between 30°C and 70°C.


The choice of solvent for this hydrolysis reaction can be quite varied, ranging from water to hydrocarbon solvents. The preferred solvent is the one that will be used in the subsequent reduction step. In this case, intermediate (VIII or VIIIa or VIIIb) can be used directly, without isolation.

Compound (VIII) and the salts (VIIIa) are prepared from the salt (VIIIb) by contacting it with a base and isolating the product by precipitation, crystallization, evaporation, etc. as is known to those skilled in the art. Almost any base with pKa greater than 3.5 can be used to make (VIII). The salt (VIIIa) must be prepared by contacting (VIIIb) with a base containing (W+). For example, the sodium salt can be prepared by contacting (VIIIb) with about two equivalents of the base sodium hydroxide.

In the present invention, it is also possible to easily remove color and impurities from the salt of intermediate (VIII) by washing it in the reactor (U.S. Patent 4,734,194 March 29, 1988)). Under the protocol exemplified hereinafter, the toluenesulphonate and methane-

sulphonate salts are found to be of particular advantage in that they filter exceptionally quickly.

As a further extension of the present invention, the sulphonic acid salt of compound (VIII), its mirror image enantiomer or a mixture of such enantiomers, is prepared by performing an oxidative hydrolysis reaction on the Diels-Alder adduct between cyclopentadiene and an alkyl or aryl sulphonyl cyanide (X).



wherein R^7 is C_{1-6} alkyl or aryl, its mirror image enantiomer or a mixture of such enantiomers. Preferred is where R^7 is methyl, phenyl, or tolyl. Most preferred is tolyl.

The literature (J.C. Jagt and A.M. vanLeusen, *J. Org. Chem.* 1974, 39, 564-566) teaches that the Diels-Alder adduct (X) is a particularly convenient precursor to the lactam (IX) by a hydrolysis reaction. Thus, by the application of an oxidative hydrolysis reaction to Diels-Alder adduct (X), compound (VIIIb) in its further preferred form can be obtained directly, and a step is saved in the overall process to prepare compound (VIIb).

The oxidative hydrolysis reaction is accomplished by contacting Diels-Alder adduct (X) with at least one equivalent of water, at least one equivalent of an oxidizing agent, and preferably a catalytic amount of an acid.

The choice of solvent can be quite varied. It is preferable to use a solvent that poses a low hazard when combined with the oxidizing agent. Most preferred is to use water as both solvent and hydrolytic agent.

Suitable oxidizing agents are those that do not oxidize a double bond. Preferred are peroxides, most preferred is hydrogen peroxide. One to five equivalents of the oxidizing agent can be used.

In the preferred embodiment where a catalytic amount of acid is used, any acid of pKa less than 3 can be used, but it is preferred that the acid used be the same as the salt of compound (VIIIb) that is formed from the Diels-Alder adduct (VIIIb). For example, if R = tolyl in the adduct (X), the oxidative hydrolysis gives the toluenesulphonate salt of compound (VIIIb). In this case, toluenesulphonic acid would be the preferred acid. If R = methyl in the adduct (X), the preferred acid would be methanesulphonic acid, etc. The amount of acid catalyst can range from 0 to 50 mol % relative to the Diels-Alder adduct (X).

All of the structures shown above are intended to represent the racemate in addition to the single enantiomer depicted. Thus, the present invention is intended to encompass both the racemates and the pure enantiomers, substantially free of their mirror-image isomers.

A compound of formula (I) may be converted into a pharmaceutically acceptable ester by reaction with an appropriate esterifying agent, e.g. an acid halide or anhydride. The compound of formula (I) including esters thereof, may be converted into pharmaceutically acceptable salts thereof in conventional manner, e.g. by treatment with an appropriate acid. An ester or salt of an ester of formula (I) may be converted into the parent compound, e.g. by hydrolysis.

The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way. The term 'active ingredient' as used in the examples means a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

Example A:

Tablet Formulations

The following formulations A and B were prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

Formulation A

	<u>mg/tablet</u>	<u>mg/tablet</u>
(a) Active ingredient	250	250
(b) Lactose B.P.	210	26
(c) Povidone B.P.	15	9
(d) Sodium Starch Glycollate	20	12
(e) Magnesium Stearate	<u>5</u>	<u>3</u>
	500	300

Formulation B

	<u>mg/tablet</u>	<u>mg/tablet</u>
(a) Active ingredient	250	250
(b) Lactose	150	-
(c) Avicel PH 101	60	26
(d) Povidone B.P.	15	9
(e) Sodium Starch Glycollate	20	12
(f) Magnesium Stearate	<u>5</u>	<u>3</u>
	500	300

Formulation C.

	<u>mg/tablet</u>
Active ingredient	100
Lactose	200
Starch	50
Povidone	5
Magnesium stearate	<u>4</u>
	359

The following formulations, D and E, were prepared by direct compression of the admixed ingredients. The lactose used in formulation E was of the direct compression type (Dairy Crest - "Zeparox").

Formulation D

	<u>mg/tablet</u>
Active Ingredient	250
Pregelatinised Starch NF15	<u>150</u>
	400

Formulation E

	<u>mg/tablet</u>
Active Ingredient	250
Lactose	150
Avicel	<u>100</u>
	500

Formulation F (Controlled Release Formulation)

The formulation was prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression.

	<u>mg/tablet</u>
(a) Active Ingredient	500
(b) Hydroxypropylmethylcellulose (Methocel K4M Premium)	112
(c) Lactose B.P.	53
(d) Povidone B.P.C.	28
(e) Magnesium Stearate	<u>7</u>
	700

Example B:Capsule FormulationsFormulation A

A capsule formulation was prepared by admixing the ingredients of Formulation D in Example 1 above and filling into a two-part hard gelatin capsule. Formulation B (infra) was prepared in a similar manner.

Formulation B

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Lactose B.P.	143
(c) Sodium Starch Glycollate	25
(d) Magnesium Stearate	<u>2</u>
	420

Formulation C

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Macrogol 4000 BP	<u>350</u>
	600

Capsules were prepared by melting the macrogol 4000 BP, dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

Formulation D

	<u>mg/capsule</u>
Active ingredient	250
Lecithin	100
Arachis Oil	<u>100</u>
	450

Capsules were prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation was prepared by extruding ingredients a, b and c using an extruder, followed by spheronisation of the extrudate and drying. The dried pellets were then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

	<u>mg/capsule</u>
(a) Active Ingredient	250
(b) Microcrystalline Cellulose	125
(c) Lactose BP	125
(d) Ethyl Cellulose	<u>13</u>
	513

Example C:Injectable FormulationFormulation A.

Active ingredient	0.200g
Hydrochloric acid solution, 0.1M	q.s. to pH 4.0 to 7.0
Sodium hydroxide solution, 0.1M	q.s. to pH 4.0 to 7.0
Sterile water	q.s. to 10ml

The active ingredient was dissolved in most of the water (35°-40°C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch was then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10ml amber glass vial (type 1) and sealed with sterile closures and overseals.

Formulation B.

Active ingredient	0.125 g
Sterile, pyrogen-free, pH 7 phosphate buffer,	q.s. to 25 ml

Example D:Intramuscular injection

Active Ingredient	0.20 g
Benzyl Alcohol	0.10 g
Glycofurol	1.45 g
Water for Injection	q.s. to 3.00 ml

The active ingredient was dissolved in the glycofurol. The benzyl alcohol was then added and dissolved, and water added to 3 ml. The mixture was then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).

Example E:

Syrup

Active ingredient	0.2500 g
Sorbitol Solution	1.5000 g
Glycerol	2.0000 g
Sodium Benzoate	0.0050 g
Flavour, Peach 17.42.3169	0.0125 ml
Purified Water	q.s. to 5.0000 ml

The active ingredient was dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate was then added to the solution, followed by addition of the sorbitol solution and finally the flavour. The volume was made up with purified water and mixed well.

Example F:

Suppository

	<u>mg/suppository</u>
Active Ingredient (63lm)*	250
Hard Fat, BP (Witepsol H15 - Dynamit Nobel)	<u>1770</u>
	2020

*The active ingredient was used as a powder wherein at least 90% of the particles were of 63lm diameter or less.

One-fifth of the Witepsol H15 was melted in a steam-jacketed pan at 45°C maximum. The active ingredient was sifted through a 200lm sieve and added to the molten base with mixing, using a silverson fitted with a cutting head, until a smooth dispersion was achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 was added to the suspension and stirred to ensure a homogeneous mix. The entire suspension was passed through a 250lm stainless steel screen and, with continuous stirring, was allowed to cool to 40°C. At a

temperature of 38°C to 40°C, 2.02g of the mixture was filled into suitable, 2 ml plastic moulds. The suppositories were allowed to cool to room temperature.

Example G:

Pessaries

	<u>mg/pessary</u>
Active ingredient (631m)	250
Anhydrate Dextrose	380
Potato Starch	363
Magnesium Stearate	<u>7</u>
	1000

The above ingredients were mixed directly and pessaries prepared by direct compression of the resulting mixture.

Antiviral Testing

Human cytomegalovirus (HCMV) is assayed in monolayers of MRC5 cells (human embryonic lung) in multiwell trays. Activity of compounds is determined in the plaque reduction assay, in which a cell monolayer is infected with a suspension of HCMV. A range of concentrations of the compound to be tested (of known molarity) is then incorporated into the carboxymethyl cellulose overlay. Plaque numbers of each concentration are expressed as percentage of the control and a dose-response curve is drawn. From this curve the 50% inhibitory concentration (IC₅₀) is estimated.

<u>Anti-HCMV Activity</u>	
<u>Compound</u>	<u>IC₅₀ (μM)</u>
Ex. 22	3.1
Ex. 23	2.8

Toxicity Testing

Compounds of formula (I) were tested for toxicity in human bone marrow progenitor cells, *in vitro*, by the method of Dornsife, R.E. *et al.*, 1991, *Antimicrob. Agents Chemother.*, **35**: 322-328. Three separate assays were performed using marrow from three different donors.

<u>Compound</u>	<u>Cell Toxicity</u>	
	<u>I₅₀ (μM) *</u>	
	<u>CFU-GM</u>	<u>BFU-E</u>
Ex. 22	34 ± 14	> 50
Ex. 23	14 ± 1	55 ± 15
2'-CDG	0.4 ± 0.3	4 ± 2

+ 50% inhibition of bone marrow progenitor cells.

Example 1(-)-(1S, 4R)-4-Amino-2-cyclopentene-1-carboxylic acid methanesulfonate

A solution of (-)-2-azabicyclo [2.2.1] hept-5-en-3-one (97.45 g, 0.8929 mol, Enzymatix Ltd.) in tetrahydrofuran (500 mL) was filtered and warmed to 35°C. A solution of methanesulfonic acid (63.7 mL, 0.9817 mol) in water (24.1 mL, 1.34 mol) was added over the course of 1.5 hours such that the ensuing exotherm did not exceed 45°C. The resulting slurry was heated at 60°C for three hours, then allowed to cool to room temperature over the course of 15 hours. The slurry was filtered and the cake washed twice with anhydrous tetrahydrofuran (200 mL). An analytical sample of the wet cake was removed and dried to give the title compound as a white solid (1.264 g); m.p. 167-169.2°C; ¹H-NMR (DMSO-*d*₆) δ: 12.6 (br s, 1H, CO₂H), 8.04 (br s, 3H, NH₃⁺), 6.10 (dt, J = 5.6, 2.0, 2.0 Hz, 1H, vinyl), 5.85 (dt, J = 5.3, 2.3, 2.3 Hz, 1H, vinyl), 4.19 (br s, w_{1/2} = 20 Hz, 1H, allylic H), 3.61 (m, w_{1/2} = 22 Hz, 1H, allylic H), 2.53 (quintet, J = 5.3 Hz (overlapping with DMSO peak), 1/2 CH₂), 2.39 (s, 3H, CH₃SO₃H), 1.93 (dt, J = 6.7, 6.7, 13.7 Hz, 1H, 1/2 CH₂); [α]_D²⁰₅₈₉ -83.8°, [α]_D²⁰₅₇₈ -87.4°, [α]_D²⁰₅₄₆ -101.2°, [α]_D²⁰₄₃₆ -186.7°, [α]_D²⁰₃₆₅ -316.2° (c = 1.42, methanol); CI-MS (CH₄): 128(M + 1); EI-MS: 127(M).

Anal. Calcd. for C₇H₁₃NO₅S: C, 37.66, H, 5.87; N, 6.27; S, 14.36.

Found: C, 37.65; H, 5.88; N, 6.30; S, 14.44.

The remaining wet cake was used directly in the following example.

Example 2

(-)-(1S, 4R)-4-Amino-2-cyclopentene-1-methanol

The tetrahydrofuran-wet cake of (-)-(1S, 4R)-4-amino-2-cyclopentene-1-carboxylic acid methanesulfonate prepared in the above example was suspended in dry tetrahydrofuran (400 mL) and transferred via cannula to a rapidly stirring solution of lithium aluminum hydride in tetrahydrofuran (1.0 molar, 1600 mL, 1.6 mol, Aldrich) cooled in an ice/acetone bath. The rate of transfer was limited to control the rate of gas evolution and to keep the temperature between 0° and 10°C (total time of addition 1.5 hours). The resulting mixture was warmed to reflux over the course of two hours, then refluxed for 16 hours.

Approximately 1.6 L of solvent was removed by distillation, the resulting slurry was cooled in an ice-acetone bath, then treated with diethyl ether (dry, 1L) and sodium fluoride (403.3 g, 9.605 mol, Aldrich). Water (86 mL, 4.8 mol) was added slowly at such a rate (three hours) that the temperature was kept below 5°C and the hydrogen evolution was moderated. The resulting slurry was filtered and the cake washed with tetrahydrofuran (200 mL), then 7% water-tetrahydrofuran (500 mL). Quantitative HPLC analysis (see Example 3, below) of the filtrate showed it to contain 60.04 g of the title compound. The cake was reslurried in 7% water-tetrahydrofuran (1L) for a half hour, filtered, and washed with 7% water-tetrahydrofuran (400 mL), then 10% water-tetrahydrofuran (300 mL). Quantitative HPLC analysis (see Example 3, below) of the filtrate showed it to contain 26.70 g of the title compound. The cake was reslurried in methanol (1L) for 16 hours, filtered, and washed with methanol (500 mL). Quantitative HPLC analysis (see Example 3, below) of the filtrate showed it to contain 4.09 g of the title compound. The total yield of the title compound was thus 90.83 g, 0.8027 mol, or 90.5% of theoretical yield corrected for the analytical sample removed.

Example 3

Analysis of (-)-(1S, 4R)-4-Amino-2-cyclopentene-1-methanol and its enantiomer, (+)-(1R, 4S)-4-amino-2-cyclopentene-1-methanol

Samples of the title compounds were characterized by the method of Brückner, H., Wittner, R., and Godel, H., "Automated Enantioseparation of Amino Acids by Derivatization with o-Phthaldialdehyde and N-Acylated Cysteines", J. Chrom., 476 (1989) 73-82. Using o-phthaldialdehyde and N-acetyl-L-cysteine as derivatizing reagents. The chromatographic separation used an Optima II ODS 100 x 4.5 mm, 3 µm column (III Supplies Co., Meriden, CT) and gradient elution at 0.9 mL/min using initially 100% sodium acetate buffer, 40 mM, pH 6.5, with a linear ramp to 18% acetonitrile over 15 minutes and a subsequent hold at 18% acetonitrile for 15 minutes. Detection was at 338 nm. Samples were dissolved in 0.1 molar borate buffer, pH 10.4. The identity and purity of the samples was established by comparison with authentic standards (see EP 434450 (June 26, 1991)). The retention time of the (1S, RS) isomer was about 21 minutes. The retention time of the (1R, 4S)- isomer was about 22 minutes.

Example 4

(-)-(1R, 4S)-tert-Butyl N-[4-hydroxymethyl]-2-cyclopenten-1-yl] carbamate

The first filtrate of Example 2 containing (-)-(1S, 4R)-4-amino-2-cyclopentene-1-methanol was cooled in an ice-acetone bath and treated with di-tert-butyl dicarbonate (199.42 g, 0.9265 mol, Aldrich). The mixture was concentrated under vacuum to a volume of 300 mL, and added to the second filtrate of Example 2 that had meanwhile been cooled in an ice-acetone bath. The mixture was allowed to stir and warm to room temperature over the course of 18 hours, during which time gas evolved and a clear solution formed. This solution was combined with the last filtrate of Example 2 which had been evaporated under vacuum to a mixture of oil and solids. The resulting solution was evaporated under vacuum to an oil. The oil was partitioned between ethyl acetate (300 mL) and phosphate buffer (100 mL of 1.5 molar potassium dihydrogen phosphate adjusted to pH 7.0 with 50% sodium hydroxide-water). The phases were separated, the aqueous phase was reextracted twice with ethyl acetate (200 mL). The organic phases were dried over sodium sulfate and filtered through silica gel (50 g.). The solvent was removed under vacuum to give an oil (220.78 g), which was

taken up in hexanes (300 mL). A minimum amount of ethyl acetate (about 50 mL) was added in order to dissolve the oil, and the solution was set to crystallize over the course of three days. The crystals were filtered off, washed with 20% ethyl acetate/hexanes, and dried by suction to a constant weight (156.1 g, 0.732 mol, 82.6% of theory) of the title compound; m.p. 73-73.7°C; $^1\text{H-NMR}$ (DMSO-d_6) δ : 6.72 (d, $J = 7.9$ Hz, 1H, NH), 5.80 and 5.60 (two m, 2H, $\text{CH} = \text{CH}$), 4.59 (t, $J = 5.2$ Hz, 1H, OH), 4.45 (m, 1H, CHN), 3.35 (m, overlapping H_2O , CH_2O), 2.60 (m, 1H, CH), 2.30 (m, 1H, $\frac{1}{2}\text{CH}_2$), 1.40 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.2 (m, 1H, $\frac{1}{2}\text{CH}_2$); $[\alpha]^{20}_{589} -2.78^\circ$, $[\alpha]^{20}_{578} -2.84^\circ$, $[\alpha]^{20}_{546} -3.06^\circ$, $[\alpha]^{20}_{436} -3.39^\circ$, $[\alpha]^{20}_{365} -0.95^\circ$ ($c = 5.07$, methanol); CI-MS (CH_4) 214 ($M + 1$); TLC (silica, 10% methanol-chloroform, iodine visualization), $R_f = 0.51$.

Anal. Calcd. for $\text{C}_{11}\text{H}_{19}\text{O}_3\text{N}$: C, 61.95; H, 8.98, N, 6.57.

Found: C, 61.87; H, 8.96; N, 6.59.

An additional 10.14 g of crystalline material was recovered from the mother liquor by crystallization and chromatography, bringing the total yield to 166.24 g (0.780 mol, 87.9% of theory from the lactam starting material of Example 1).

It was also found convenient to prepare the title compound directly from 2-azabicyclo [2.2.1] hept-5-en-3-one, either racemic or the (-) enantiomer, as follows. (-)-2-Azabicyclo [2.2.1] hept-5-en-3-one (6.00 g, 55.0 mmol) in anhydrous tetrahydrofuran (30 mL) was warmed to 34°C and stirred while methanesulfonic acid (3.6 mL, 55 mmol) and water (0.99 mL, 55 mmol) were added dropwise over 10 minutes. An exotherm of 10°C was observed within 5 minutes and a crystalline solid began to precipitate. The mixture was refluxed (oil bath at 74°C) for 2.5 hours. The mixture was cooled to -10°C and a solution of lithium aluminum hydride (1.0 M in tetrahydrofuran, 100 mL) added. The first 15 mL was added over 10 minutes and an exotherm of 7°C noted. The remaining 85 mL was added rapidly with no further exotherm noted. The mixture was brought to reflux over 30 minutes and reflux continued for 18 hours. The mixture was cooled to 25°C and sodium fluoride (25.2 g, 0.600 mole) was added and, after stirring for 30 minutes water (5.3 mL) was added dropwise over 10 minutes to the cooled (0°C) mixture. The mixture was stirred for 30 minutes at 25°C and di-tert-butyl dicarbonate (12.6 mL, 55.0 mmol) was added. This mixture was stirred for 16 hours, filtered, and the cake triturated with ethyl acetate (2 x 50 mL). The combined filtrate-wash was washed with water (20 mL), dried (Na_2SO_4), evaporated, and the residual syrup crystallized from ethyl acetate:hexanes / 1:2 (30 mL) to give title compound as white crystals (10.32 g, 88%), identical in properties to the above-described sample.

Example 5(-)-(1R, 2S, 3R, 4R)-tert-Butyl N-[2,3-dihydroxy-4-(hydroxymethyl)-1-cyclopentyl] carbamate

To a mixture of N-methyl morpholine-N-oxide (146.2 g, 60% in water, 0.749 mol) and osmium tetroxide (9.75 g, 2.5% in tert-butanol, 0.959 mmol) in acetone (1L) stirring at -8°C in an ice-acetone bath was added in one portion (-)-(1R, 4S)-tert-butyl N-[4-hydroxymethyl]-2-cyclopenten-1-yl] carbamate (152.10 g, 0.7132 mol, from the preceding Example). The resulting mixture was allowed to warm to room temperature over 16 hours, during which time it became homogeneous. More osmium tetroxide was added (2.602 g, 0.256 mmol), and the solution was stirred at 20°C for four hours, then 40° for two hours, at which time the reaction was judged complete by TLC (silica, 10% methanol-chloroform, visualization with iodine followed by vanillin char, starting material: $R_f = 0.51$, products: $R_f = 0.22$, (2S, 3R)-isomer, and $R_f = 0.36$, (2R, 3S)-isomer). The ratio of (2S, 3R) / (2R, 3S) isomers was about 73:27 as judged by $^1\text{H-NMR}$ and TLC. Water (75 mL) was added, followed by chloroform (2 L). The resulting two-phase mixture was cooled in an ice bath, and with very gentle agitation (to discourage phase mixing), anhydrous copper sulfate (457.8 g, Alfa) was added in several portions. The resulting slurry was allowed to stir at room temperature about 16 hours, then was filtered with filter aids (Celite 545 and 512). The cake was washed with tetrahydrofuran (6 L) until no more product eluted. The filtrate was evaporated under vacuum to a dark oil substantially free of N-methyl morpholine. The oil was filtered through silica gel (300 g), and eluted with tetrahydrofuran (3 L) until all of the product was eluted. The eluate was concentrated to 200 mL, and hexanes (about 300 mL) was added. Crystallization began spontaneously, and was allowed to continue at -5°C for about 16 hours. The crystals were recovered by filtration, washed sparingly with 50% ethyl acetate-hexanes, and dried by suction to a constant weight (105.78 g, 0.428 mol, 60.0% of theoretical). Recrystallization from refluxing ethyl acetate (200 mL) provided the title compound as white crystals (93.85 g, 0.3795 mol, 53.2% of theoretical); m.p. 115.8-117°; $^1\text{H-NMR}$ (DMSO- d_6) δ : 6.71 (br d, $J = 7.4$ Hz, 1H, NH), 4.52 (t, $J = 5.2$ Hz, 1H, CH_2OH), 4.43 (d, $J = 5.1$ Hz, 1H, CHOH), 4.31 (d, $J = 4.9$ Hz, 1H, CHOH), 3.54-3.41 (overlapping multiplet, 3H, CHN and CHOH), 3.34 (m, overlapping with HOD, $w_{1/2} = 20$ Hz, CH_2OH), 1.99 (dt, $J = 12.5, 6.8, 6.8$ Hz, 1H, HOCH_2CH), 1.85 (br. m, $w_{1/2} = 30$ Hz, 1H, $\frac{1}{2}\text{CH}_2$), 1.39 (s, 9H, $\text{C}(\text{CH}_3)_3$), 0.98 (dt, $J = 12.4, 7.8, 7.8$ Hz, 1H, $\frac{1}{2}\text{CH}_2$); $[\alpha]^{20}_{589} -8.08^\circ$, $[\alpha]^{20}_{578} -8.57^\circ$, $[\alpha]^{20}_{546} -9.95^\circ$, $[\alpha]^{20}_{436} -18.22$, $[\alpha]^{20}_{365} -29.36^\circ$ ($c = 1.02$, methanol); CI-MS (CH_4) 248(M + 1).

Anal. Calcd. for $\text{C}_{11}\text{H}_{21}\text{O}_5\text{N}$: C, 53.43; H, 8.56; N, 5.66.

Found: C, 53.45; H 8.58; N, 5.69.

A sample of the (-)-(2R, 3S)-isomer (25.60 g) was obtained from the mother liquors by fractional crystallization from ethyl acetate; m.p. 106-107.2°C; ¹H-NMR (DMSO-d₆) δ: 5.93 (br d, J = 7.6 Hz, 1H, NH), 4.77 (d, J = 4.9 Hz, 1H, CHOH), 4.58 (d, J = 4.1 Hz, 1H, CHOH), 4.35 (br t, w_{1/2} = 15 Hz, 1H, CH₂OH), 3.89 (br s, w_{1/2} = 10 Hz, 1H, OCH), 3.73 (br s, 2H, OCH, NCH), 3.50 (br m, w_{1/2} = 20 Hz, 1H, $\frac{1}{2}$ OCH₂), 3.38 (br m, obscured by HOD, $\frac{1}{2}$ OCH₂), 1.90 (m, w_{1/2} = 24 Hz, 2H, OCH₂CH, $\frac{1}{2}$ CH₂), 1.38 (s, 9H, C(CH₃)₃), 1.27 (m, 1H, $\frac{1}{2}$ CH₂); [α]_D²⁰₅₈₉ -7.92°, [α]_D²⁰₅₇₈ -8.14°, [α]_D²⁰₅₄₆ -9.05°, [α]_D²⁰₄₃₆ -14.81°, [α]_D²⁰₃₆₅ -21.19° (c = 1.36, methanol); CI-MS (CH₄), 248(M + 1).

Anal. Calcd. for C₁₁H₂₁O₅N, 0.05 H₂O: C, 53.23; H, 8.57; N, 5.64.

Found: C, 53.20; H, 8.55; N, 5.61.

Example 6

(-)-(6aR, 8R, 9S, 9aR)-tert-Butyl N-(hexahydro-9-hydroxy-2,2,4,4-tetraisopropyl cyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate

The product of the preceding Example, (-)-(1R, 2S, 3R, 4R)-tert-butyl N-[2,3-dihydroxy-4-(hydroxymethyl)-1-cyclopentyl] carbamate (92.97 g, 0.3760 mol) and imidazole (103.0 g, 1.513 mol, Aldrich) were dissolved in dry N,N-dimethylformamide (200 mL, Aldrich) and cooled to -7°C in an ice-acetone bath. With rapid stirring, 1,3-dichloro-1,1,3,3-tetraisopropyl disiloxane (121.2 g, 0.3842 mol, Cambridge, refractionated) was run in at once (about $\frac{1}{2}$ minute), and immediately washed in with cyclohexane (10 mL). An immediate exotherm carried the temperature to 35°C, then subsided. At 10°C, the cooling bath was removed and the mixture was allowed to stir at room temperature for two days. The reaction mixture was partitioned between cyclohexane and ice water (200 mL each). The lower phase (pH = 7) was extracted with two additional portions of cyclohexane (200 mL each), and each of the organic extracts was then washed in sequence with four portions of water (150 mL) and one portion of saturated aqueous sodium sulfate. The organic phases were dried over anhydrous sodium sulfate, then filtered and concentrated under vacuum to a volume of about 250 mL (slightly yellow solution), which was used directly in the following Example.

A sample of the title compound prepared similarly but purified by chromatography on silica gel (eluted with 20% ethyl acetate-hexanes) gave a colorless glass, which crystallized on standing with the following characteristics; m.p. 63.5-65.2°C; ¹H-NMR (DMSO-d₆) δ: 6.96 (br d, J = 4.8 Hz, 1H, NH), 4.24 (d, J = 4.8 Hz, 1H, OH), 3.93 (dd, J = 7.3, 5.5 Hz, 1H, NCH), 3.83 (dd,

$J = 13, 2.7 \text{ Hz}$, 1H, OCH), 3.65 (q, $J = 4.7 \text{ Hz}$, 2H, CH_2O), 3.53 (br d, $J \sim 6 \text{ Hz}$, 1H, OCH), 2.09-1.80 (br m, 2H, CH and $\frac{1}{2} \text{CH}_2$), 1.39 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.04 (m, $w_{\frac{1}{2}} = 13 \text{ Hz}$, 29H, CH $(\text{CH}_3)_2$ and $\frac{1}{2} \text{CH}_2$, obscured); $[\alpha]^{20}_{589} -15.45^\circ$, $[\alpha]^{20}_{578} -16.23^\circ$, $[\alpha]^{20}_{546} -19.21^\circ$, $[\alpha]^{20}_{436} -33.62^\circ$, $[\alpha]^{20}_{365} -52.43^\circ$ ($c = 0.779$, methanol, corrected for 0.3 H_2O); CI-MS (CH_4): 490($M + 1$); TLC (silica, 20% ethyl acetate-hexanes, iodine visualization) $R_f = 0.46$.

Anal. Calcd. for $\text{C}_{23}\text{H}_{47}\text{NO}_6\text{Si}_2 \cdot 0.3\text{H}_2\text{O}$: C, 55.79; H, 9.69; N, 2.83.

Found: C, 55.81; H, 9.57; N, 2.82.

Example 7

(-)-(6aR, 8R, 9S, 9aR)-tert-Butyl N-(hexahydro-2,2,4,4-tetraisopropyl-9-(phenoxithiocarbonyl)oxy)-cyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate

The solution of (-)-(6aR, 8R, 9S, 9aR)-tert-butyl N-(hexahydro-9-hydroxy-2,2,4,4-tetraisopropylcyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate (0.3760 mol) in cyclohexane, obtained in the preceding Example was diluted to a total volume of 500 mL with cyclohexane. N-Hydroxysuccinimide (8.568 g, 74.45 mmol), and pyridine (33.2 mL, 0.410 mol) were added, then with rapid stirring, a solution of phenyl thionochloroformate (70.8 g, 0.410 mol) in cyclohexane (50 mL) was added dropwise over the course of 20 minutes. The resulting dark mixture was stirred for 16 hours at room temperature, then refluxed for four hours. Pyridine (7.1 mL, 88 mmol), then phenylthionochloroformate (15.09 g, 87.41 mmol) were added, and the mixture was refluxed for three hours. Pyridine (5.0 mL, 62 mmol) and phenylthionochloroformate (9.903 g, 57.37 mmol) were added, and the mixture was refluxed an additional 3.5 hours, at which time it was judged complete by TLC (silica, 20% ethyl acetate-hexanes, visualization with iodine followed by vanillin char; starting material: $R_f = 0.46$, product: $R_f = 0.49$). The mixture was distilled to a volume of about 400 mL, cooled to room temperature, then filtered through a bed of filter aid (1 cm, Celite 545) under a dry nitrogen atmosphere. The resulting cake of pyridine hydrochloride was washed with cyclohexane (200 mL), to give a solution of the title compound in cyclohexane.

A sample prepared similarly, but purified by chromatography on silica gel (eluted with 10% ethyl acetate-hexanes) gave a colorless oil with the following characteristics; $^1\text{H-NMR}$ (DMSO-d_6), δ : 7.56-7.28 (m, 4H, o- and m-ArH), 7.11 (br d, $J = 7.3 \text{ Hz}$, 2H, NH and p-ArH), 5.49 (dd, $J = 5.3, 3.3 \text{ Hz}$, 1H, SCOCH), 4.33 (br m, $w_{\frac{1}{2}} = 20 \text{ Hz}$, 1H, NCH), 3.88 (m, 2H, $\frac{1}{2}\text{CH}_2\text{O}$ and OCH), 3.71 (br dd, $J \sim 12, 3 \text{ Hz}$, 1H, $\frac{1}{2}\text{OCH}_2$), 2.11-1.88 (br m, 2H, $\frac{1}{2}\text{CH}_2$ and CH), 1.40 (s, 9H,

$C(CH_3)_3$, 1.05 (d, $J = 4.9$ Hz, overlapping with multiplet, 29H, $\frac{1}{2}CH_2 + 4CH(CH_3)_2$); $[\alpha]^{20}_{589} - 3.17^\circ$, $[\alpha]^{20}_{578} - 33.1^\circ$, $[\alpha]^{20}_{546} - 37.4^\circ$, $[\alpha]^{20}_{436} - 61.3^\circ$, $[\alpha]^{20}_{365} - 71.4^\circ$ ($c = 1.19$, methanol, corrected for 0.15 methylene chloride, 0.10 ethyl acetate and 0.10 water);

Anal. Calcd. for $C_{30}H_{51}O_7NSi_2S \cdot 0.15CH_2Cl_2 \cdot 0.10C_4H_8O_2 \cdot 0.10H_2O$: C, 56.51; H, 8.12; N, 2.16; S, 4.94.

Found: C, 56.77; H, 8.41; N, 2.19; S, 4.98.

Example 8

(-)-(6aR, 8R, 9aS)-tert-Butyl N-(hexahydro-2,2,4,4-tetraisopropylcyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate

The cyclohexane solution of (6aR, 8R, 9S, 9aR)-tert-butyl N-(hexahydro-2,2,4,4-tetraisopropyl-9-[(phenoxythiocarbonyl)oxy]-cyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate (0.3760 mol) prepared in the previous Example was degassed under a nitrogen atmosphere. Tributyltin hydride (207.4 g, 0.713 mol) and 2,2'-azo bis (2-methylpropionitrile) (12.79 g, 77.86 mmol) were added, the degassing was repeated, and the black solution was refluxed for four hours, during which time it turned to an amber color, and the reaction was judged complete by TLC (silica, 20% ethyl acetate-hexanes, visualized with iodine followed by vanillin char, starting material: $R_f = 0.49$, product: $R_f = 0.36$, white spot). The reaction solution was cooled to room temperature and added to 5% ammonium hydroxide-water (500 mL). The lower (aqueous) phase was extracted with two portions of hexane (200 mL each), and each of the organic extracts was then washed in sequence with 5% aqueous ammonia (two 500 mL portions, to remove phenol) water (500 mL), and saturated aqueous sodium sulfate (200 mL). The combined organic extracts were dried over sodium sulfate, then applied to a column of silica gel (about 1 Kg), which was eluted with hexanes (1 L), 5% ethyl acetate-hexanes (1 L), 20% ethyl acetate-hexanes (1 L) and ethyl acetate. All fractions containing product were evaporated to an amber oil (322.5 g). This was further purified by chromatography on two columns of silica gel (1 Kg each, eluted with an ethyl acetate-hexanes gradient) giving the title compound in two portions as an oil (74.32 g and 73.82 g, respectively, total 148.14 g, 0.313 mol, 83.2% of theoretical from the triol product of Example 5). A sample prepared similarly, but taken as the central fraction of the chromatography gave a colorless, crystallizing glass with the following characteristics: m.p. 66-67.0°C; 1H -NMR (DMSO- d_6), δ : 6.93 (br d, $J = 6$ Hz, 1H, NH), 4.22 (q, $J = 6.8$ Hz, 1H, NCH), 3.84 (dd, $J = 3.1, 11.5$ Hz, 2H, CH_2O), 3.61 (dd, $J = 6.5, 9$ Hz, 1H, OCH), 1.91-1.73 (br m, 4H, CH, $\frac{1}{2}CH_2$, CH_2), 1.38 (s, 9H, $C(CH_3)_3$), 1.02 (m, $w_{\frac{1}{2}} = 21$ Hz, 29H, 4CH (CH_3) $_2$ and $\frac{1}{2}CH_2$,

obscured); $[\alpha]^{20}_{589} -2.78^\circ$, $[\alpha]^{20}_{578} -2.84^\circ$, $[\alpha]^{20}_{546} -3.06^\circ$, $[\alpha]^{20}_{436} -3.39^\circ$, $[\alpha]^{20}_{365} -0.95^\circ$ ($c = 5.07$, methanol); CI-MS (CH_4): 474($M + 1$).

Anal. Calcd. for $\text{C}_{23}\text{H}_{47}\text{NO}_5\text{Si}_2$ C, 58.31; H, 10.00; N, 2.96.

Found: C, 58.33; H, 10.00; N, 2.97.

Example 9

(+)-(1R, 3S, 4R)-tert-Butyl N-[3-hydroxy-4-(hydroxymethyl)-1-cyclopentyl] carbamate

To a solution of (–)-(6aR, 8R, 9aS)-tert-butyl N-(hexahydro-2,2,4,4-tetraisopropylcyclopenta [f]-1,3,5,2,4-trioxadisilocin-8-yl) carbamate (74.32 g, 0.1569 mol, corresponding to the first portion of product in the above Example) in tetrahydrofuran (300 mL) was added tetraethyl ammonium fluoride hydrate (24.62 g, about 0.15 mol, Aldrich). The lumps of solid were broken up, the mixture was degassed (nitrogen), then refluxed for 45 minutes. After cooling to room temperature, the reaction mixture was applied to a column of silica gel (200 g) and eluted with tetrahydrofuran (3 L). The eluate was concentrated under vacuum to an amber oil, which was taken up in hexanes (150 mL). Crystallization began spontaneously, and was allowed to continue at -5° for two days. The crystals of crude title compound were collected by filtration, washed sparingly with 10% ethyl acetate-hexanes, and dried by suction to constant weight (25.08 g, 0.1084 mol). The procedure was repeated on the second portion of product from the above Example (73.82 g, 0.1558 mol), giving additional crude title compound (27.28 g, 0.1180 mol). The two portions of crude title compound were combined and recrystallized from boiling ethyl acetate (250 mL), giving white crystals of the title compound (46.67 g., 0.2018 mol, 53.7% of theoretical from the triol product of Example 5) having the following characteristics: m.p. $126-127.9^\circ\text{C}$; $^1\text{H-NMR}$ ($\text{DMSO}-d_6$), δ : 6.75 (br d, $J = 7.8$ Hz, 1H, NH), 4.49 (t, $J = 4.5$ Hz, CH_2OH) overlapping 4.47 (d, $J = 4.3$ Hz, CHOH) with total integration of 2H, 3.80-3.93 (m, 2H, CHN and CHOH), 3.34 (m, $w_{1/2} = 20$ Hz, CH_2OH), 2.25 (dt, 1H, CHCH_2), 1.79-1.63 (m, 2H, CH_2CHOH), 1.63-1.50 (m, 1H, $\frac{1}{2}\text{CH}_2$), 1.38 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.11-0.96 (m, 1H, $\frac{1}{2}\text{CH}_2$); CI-MS (CH_4): 232($M + 1$).

Anal. Calcd. for $\text{C}_{11}\text{H}_{21}\text{O}_4\text{N}$: C, 57.12; H, 9.15; N, 6.06.

Found: C, 57.07; H, 9.12; N, 6.08.

A chromatographically homogeneous sample of the title compound prepared similarly showed: $[\alpha]^{20}_{589} + 15.4^\circ$, $[\alpha]^{20}_{578} + 16.0^\circ$, $[\alpha]^{20}_{546} + 18.2^\circ$, $[\alpha]^{20}_{436} + 30.1^\circ$, $[\alpha]^{20}_{365} + 43.7^\circ$ ($c = 0.51$, methanol, corrected for 0.13 H_2O solvation).

Example 10(+)-(1S, 2R, 4R)-4-Amino-2-(hydroxymethyl)-1-cyclopentanol

The product of the preceding Example, (+)-(1R, 3S, 4R)-tert-butyl N-[3-hydroxy-4-(hydroxymethyl)-1-cyclopentyl] carbamate (2.351 g, 10.17 mmol) was slurried in aqueous hydrochloric acid (1.0 molar, 25.4 mL, 25.4 mmol) and heated gently (60-80°C) until a colorless solution formed, and the gas evolution subsided (about 15 minutes). The solution was allowed to cool to room temperature, then was concentrated under vacuum to a syrup, which was taken up in water (about 20 mL) and reconcentrated. The resulting syrup of hydrochloride salt was applied to a column of quaternary amine ion exchange resin (about 50 mL of Amberlite IRA-400, hydroxide form, washed to neutrality with water), and eluted with water (500 mL). The water was evaporated under vacuum, leaving the title compound as a colorless syrup (1.62 g). ¹H-NMR (DMSO-d₆), δ: 3.90 (dt, J = 4.7, 4.7, 6.4 Hz, 1H, NCH), 3.47-3.23 (m, obscured by broad OH peak, ~3H, CH₂O and CHO), 1.97 (dt, J = 7.3, 7.3, 12.7 Hz, 1H, CHCH₂OH), 1.78 (br sextet, J = 5Hz, 1H, $\frac{1}{2}$ CH₂), 1.61 (m, w $\frac{1}{2}$ = 22Hz, 1H, $\frac{1}{2}$ CH₂), 1.47 (m, w $\frac{1}{2}$ = 30Hz, 1H, $\frac{1}{2}$ CH₂), 0.94 (dt, J = 7.2, 7.2, 12.3 Hz, 1H, $\frac{1}{2}$ CH₂); [α]_D²⁰₅₈₉ + 35.9°, [α]_D²⁰₅₇₈ + 37.3°, [α]_D²⁰₅₄₆ + 42.3°, [α]_D²⁰₄₃₆ + 69.9°, [α]_D²⁰₃₆₅ + 103.0° (c = 2.49 methanol, corrected for 1.3 H₂O); CI-MS (CH₄): 132(M + 1).

Anal. Calcd. for C₆H₁₃O₂N·1.3H₂O: C, 46.62; H, 10.17; N, 9.06.

Found: C, 46.61; H, 9.99; N, 8.93.

Example 11(±)-cis-4-Amino-2-cyclopentene-1-carboxylic acid, 4-toluenesulfonate

A 500 mL, three-neck flask with vertical joints was charged with (±)-2-azabicyclo [2.2.1] hept-5-en-3-one (48.66 g, 0.4459 mol, Cambridge), and equipped with a mechanical stirrer, thermometer with gas inlet adapter connected to the nitrogen supply, and a powder funnel. Tetrahydrofuran (200 mL, reagent grade) was added, and the stirrer started in order to dissolve the solid. An endotherm of 13°C was noted. A gentle nitrogen sweep was applied from the inlet adapter out the powder funnel and 4-toluene sulfonic acid hydrate (93.52 g, 0.416 mol, 1.1 equiv) was added, along with a small amount of the title compound as seed. The powder funnel was replaced by a reflux condenser, and the flask was immersed in an oil bath preequilibrated to 35°C. Within 10 minutes, crystallization began, followed by

an exotherm peaking at 60°C in another 15 minutes. After the exotherm peaked, the bath was reset to 60-65°C, and the reaction mixture was heated two hours at 60-65°C (internal), until a TLC of the supernatant liquid (silica, ethyl acetate eluent, iodine visualization) shows the absence of starting lactam against an authentic spot. The mixture was then cooled in an ice bath to ~5°C. A glass tube with a fritted end was connected via flexible tubing to a filter flask, in turn connected to a vacuum source. The condenser was removed from the flask containing the slurry, the stirrer was stopped, and with a nitrogen sweep from the gas inlet, the fritted end of the stick was pushed to the bottom of the flask under the agitator. Vacuum was applied until the liquid was completely removed, the solids were reslurried in dry tetrahydrofuran (100 mL), and the filtration operation was repeated. The resulting white solids were reslurried in dry tetrahydrofuran (200 mL), and the open neck was capped with a septum. The resulting slurry of the title compound was used directly in the following Example; an analytical sample was prepared similarly, except that it was dried first by suction then by the application of vacuum; m.p. 191-193°C; ¹H-NMR (DMSO-d₆), δ: 12.62 (br s, 1H, CO₂H), 7.93 (br s, 3H, NH₃⁺), 7.47 and 7.11 (dd, 8.0 Hz, 2H each, Ar-H), 6.11 (dt, J = 5.7, 1.9, 1.9, Hz, 1H, vinyl), 5.82 (dt, J = 5.7, 2.8, 2.8 Hz, 1H vinyl), 4.20 (br m, w_{1/2} = 21 Hz, 1H, allylic H), 3.61 (br tt?, w_{1/2} = 21 Hz, 1H, allylic), 2.29 (s, 3H, CH₃), 2.50 (dt?, J = 5.8, 5.8, 11.5 Hz, (overlapping DMSO peak), $\frac{1}{2}$ CH₂), 1.92 (dt, J = 6.7, 6.7, 13.4 Hz, 1H, $\frac{1}{2}$ CH₂).

Anal. Calcd. for C₁₃H₁₇O₅N₅: C, 52.16; H, 5.72; N, 4.68; S, 10.71.

Found: C, 52.16; H, 5.76; N, 4.66; S, 10.62.

Example 12

(±)-cis-4-Amino-2-cyclopentene-1-methanol

A dry, 2L, three-neck flask was equipped with a mechanical stirrer, thermometer with gas inlet adapter connected to the nitrogen supply, and septum. The flask was purged with nitrogen, immersed in an ice-acetone bath, and lithium aluminum hydride solution in tetrahydrofuran (1.0 molar, 800 mL, 0.80 mol, Aldrich) was added via cannula. Dry tetrahydrofuran (2x15 mL) was used to rinse in the lithium aluminum hydride solution. When the solution had cooled to 0°C, the slurry of (±)-cis-4-amino-2-cyclopentene-1-carboxylic acid 4-toluenesulfonate salt in tetrahydrofuran prepared in the previous Example was cannulated in with good stirring, at such a rate as to keep the temperature less than 10°C and moderate the hydrogen evolution (about one hour). The flask was rinsed with dry tetrahydrofuran (2x15 mL), and the septum was replaced with a reflux condenser. The resulting clear, light amber solution was slowly warmed to a gentle reflux over the course of

two hours, at which point it became cloudy. After refluxing overnight (16 hours), the heating bath was dropped, sodium fluoride (136.3 g, 3.25 mol, reagent grade powder) was added, and the condenser reset for downward distillation. The mixture was distilled to a thin slurry (700 mL of distillate collected), then cooled in an ice bath. Diethyl ether (dry, 500 mL) was added, and the condenser was replaced by an addition funnel containing water (43 mL, 2.4 mol). The water was added very slowly (two hours), with care taken to control the rate of hydrogen evolution and maintain the temperature at $10 \pm 5^\circ\text{C}$. Meanwhile, water (54 mL) was added to the above recovered distillate, and sufficient additional tetrahydrofuran was added to bring the total volume to 900 mL (6% H_2O). The reaction mixture was filtered by suction, and the cake displace-washed with tetrahydrofuran (100 mL). Part of the 6% water-tetrahydrofuran solution (300 mL) was used to slurry-wash the cake, which was then returned to the reaction flask. The cake was triturated (25 minutes) in 6% water-tetrahydrofuran (400 mL), filtered, and displace-washed with 6% water-tetrahydrofuran (200 mL). The combined filtrates were concentrated to a pale yellow oil under vacuum (44.07 g, 67.8% by HPLC; see Example 3). The oil, containing pure title compound, water, and a trace of tosylate salt, darkens rapidly under ambient conditions. It was immediately reacted to form the N-BOC derivative, a stable, crystalline solid, (see the following Example). The filter cake was returned to the flask and triturated in methanol (800 mL) for 48 hours. The resulting slurry was filtered under a rubber dam, and the cake was washed with methanol (200 mL). The filtrate was concentrated under vacuum to a yellow solid (56.80 g, 20.9% yield by HPLC; total overall yield 88.7%). This extract was also taken to the N-BOC derivative (see the following Example).

Example 13

(\pm)-cis-tert-Butyl N-[4-(hydroxymethyl)-2-cyclopenten-1-yl] carbamate

The first extract of the previous example containing (\pm)-cis-4-Amino-2-cyclopentene-1-methanol (0.4459 mol) was dissolved in 2:1 1,4-dioxane-water (1.2L). Sodium bicarbonate (48.69 g, 0.580 mol) was added, the mixture was cooled in an ice-water bath and di-tert-butylidicarbonate (110.25 g, 0.490 mol, Aldrich 97%) was added in one portion with rapid stirring. The resulting mixture was warmed to room temperature over the course of one hour, then was concentrated under vacuum to a volume of about 400 mL. The slurry was taken up in chloroform (300 mL), the phases were separated, and the aqueous (upper) phase was reextracted with chloroform (five portions of 300 mL each) until no product was observed in the extract by TLC (silica, 10% methanol-chloroform, iodine visualization,

R_f = 0.51). The combined organic phases were dried over sodium sulfate, filtered and concentrated under vacuum to give the title compound as an oil. The final extract of the previous example was reacted similarly, and the crude title compound thus obtained was combined with the above portion, the combined material was taken up in hexanes and evaporated under vacuum to remove residual chloroform. The oil then crystallized spontaneously. It was triturated in cold hexanes and filtered to give the crude title compound as a crystalline solid, which was dried by suction to a constant weight (79.98 g, 0.3750 mol). Recrystallization from boiling ethyl acetate (70 mL) and hexanes (300 mL) gave the title compound as a off-white, crystalline solid (73.43 g, 0.3443 mol); m.p. 54-55.5°C; ¹H-NMR (DMSO-d₆) δ: 6.72 (d, J = 7.9 Hz, 1H, NH), 5.80 and 5.60 (two m, 2H, CH = CH), 4.59 (t, J = 5.2 Hz, 1H, OH), 4.45 (m, 1H, CHN), 3.35 (m, overlapping H₂O, CH₂O), 2.60 (m, 1H, CH), 2.30 (m, 1H, $\frac{1}{2}$ CH₂), 1.40 (s, 9H, C(CH₃)₃), 1.2 (m, 1H, $\frac{1}{2}$ CH₂).

Anal. Calcd. for C₁₁H₁₉NO₃: C, 61.94; H, 8.98; N, 6.57.

Found: C, 62.00; H, 8.99; N, 6.55.

The mother liquors were combined, chromatographed on silica gel (700 g, 30% ethyl acetate-hexanes and 5% methanol-chloroform), and crystallized as above to give a second portion of the title compound (10.49 g, 0.0492 mmol). The total yield was thus 0.3935 mol, or 88.9% of theoretical from the starting (±)-2-azabicyclo [2.2.1] hept-5-en-3-one (corrected for aliquots taken).

Example 14

(±)-cis-4-Amino-2-cyclopentene-1-methanol

By the method of Examples 11 and 12, but on about twice the scale (97.40 g, 0.8924 mol of (±)-2-azabicyclo[2.2.1] hept-5-en-3-one) the title compound was obtained as extracts containing the title compound (0.7926 mol, 88.8% of theoretical, allowing for aliquots removed, as determined by the method of Example 3).

EXAMPLE 15

(±)-cis-tert-Butyl N-(4-[hydroxymethyl]-2-cyclopenten-1-yl) carbamate

The combined tetrahydrofuran extracts from the preceding Example were concentrated under vacuum to 1031 g, cooled in an ice-water bath, and a mixture of sodium bicarbonate (97.46 g, 1.16 mol) in water (500 mL) was added. This was followed by di-tert-butyl dicarbonate (204.5 g, 0.9501 mol). The mixture was stirred at 5°C for two days. The

methanol extracts from the preceding Example were evaporated to an oily solid (136.64 g), which was added to the mixture. After warming to room temperature, the organic solvents were evaporated under vacuum, and the resulting slurry was extracted with hexanes, three portions of methylene chloride, then hexanes again (200 mL each). The organic extracts were evaporated to an oil, which was crystallized from hexanes (about 300 mL), giving the title compound (154.15 g, 0.7229 mol), identical to the product of Example 13. Additional product was obtained by chromatography of the mother liquors (10.5 g, 0.0491 mol, 86.6% of theoretical from the starting lactam, allowing for aliquots removed).

Example 16

(±)-cis-4-Amino-2-cyclopentene-1-carboxylic acid, methanesulfonate

Beginning with (±)-2-azabicyclo[2.2.1] hept-5-en-3-one (5.111 g, 46.83 mmol, Cambridge), by the method of Example 1, was prepared the title compound (10.268 g, 45.99 mmol, 98.2%); m.p. 137-139°C; ¹H-NMR (DMSO-d₆) δ: 12.6 (br s, 1H, CO₂H), 8.04 (br s, 3H, NH₃⁺), 6.10 (dt, J = 5.6, 2.0, 2.0 Hz, 1H, vinyl), 5.85 (dt, J = 5.3, 2.3, 2.3 Hz, 1H, vinyl), 4.19 (br s., w_{1/2} = 20 Hz, 1H, allylic H), 3.61 (m, w_{1/2} = 22 Hz, 1H, allylic H), 2.53 (quintet, J = 5.3 Hz (overlapping with DMSO peak), 1/2 CH₂), 2.39 (s, 3H, CH₃SO₃H), 1.93 (dt, J = 6.7, 6.7, 13.7 Hz, 1H, 1/2 CH₂); CI-MS (CH₄): 128(M + 1); EI-MS: 127(M).

Anal. Calcd. for C₇H₁₃NO₅S: C, 37.66; H, 5.87; N, 6.27; S, 14.36

Found: C, 37.60; H, 5.85; N, 6.25; S, 14.30

Example 17

(±)-cis-4-Amino-2-cyclopentene-1-carboxylic acid, 4-toluenesulfonate

To a solution containing a catalytic amount of 4-toluene sulfonic acid (10 mg) in 30% aqueous hydrogen peroxide (0.30 mL, 2.7 mmol) was added 3-tosyl-2-azabicyclo [2.2.1] hepta-2,5-diene (369 mg, 1.49 mmol), prepared by the method of J.C. Jagt and A.M van Leusen, J. Org. Chem. 1974, 39, 564-566, in portions, with rapid stirring. A large exotherm is noted, stabilizing at 75°C during the last half of the addition. After stirring 70°C for 40 minutes, the mixture was repeatedly diluted with water (6 mL total) and filtered until a clear solution resulted. The solution was evaporated to an oil which crystallized (349 mg). This was triturated in tetrahydrofuran, filtered, and dried under vacuum to give the title

compound (202 mg, 45.2% of theoretical), ^1H -NMR spectrum identical to the product of Example 11.

Example 18

(\pm)-(IR*, 2S*, 4S*) - 4 - [2-Amino-6-(Cyclopropylmethylamino)-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol Dihydrochloride)

(\pm) - (IR*, 2S*, 4S*) - 4- (2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol (250 mg, 0.88 mmol) (Shealy et al.; U.S. Patent 4,543,255; September 24, 1985) ethanol (1 mL), and cyclopropylmethylamine (4.0 mL) were refluxed under nitrogen for 1.5 hours. The cooled solution was evaporated to dryness after the addition of 1N sodium hydroxide (0.88 mL). The residue was absorbed on silica gel. Title compound was eluted from a silica gel column with 5% methanol-chloroform as a colorless glass (220 mg). The glass was dissolved in absolute ethanol (8.5 mL) and diluted with 1M hydrochloric acid in diethyl ether (5 mL). The resulting white precipitate was washed with diethyl ether and dried to give the dihydrochloride of title compound as white powder (210 mg, 48%), m.p. > 250°C; mass spectrum (CI), 301 (M + 1).

Anal. Calcd. for $\text{C}_{15}\text{H}_{22}\text{N}_6\text{O}_2 \cdot 2\text{HCl}$: C, 46.04; H, 6.18, N, 21.48; Cl, 18.12.

Found: C, 46.00; H, 6.21; N, 21.36; Cl, 18.05.

Example 19

(\pm)-(IR*, 2S*, 4S*)-4-[2-Amino-6-(cyclopropylamino) -9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol Dihydrochloride

In the same manner as example 18, with cyclopropylamine, title compound was obtained as its dihydrochloride from ethanol-ether as a white powder (272 mg, 85% yield from 0.9 mmol of the 6-chloropurine), m.p. > 250°; mass spectrum (CI), 305 (M + 1).

Anal. Calcd. for $\text{C}_{14}\text{H}_{20}\text{N}_6\text{O}_2 \cdot 2\text{HCl} \cdot 0.85 \text{H}_2\text{O}$: C, 42.83; H, 6.08; N, 21.41; Cl, 18.06.

Found C, 42.84; H, 6.08; N, 21.40; Cl, 18.04.

Example 20(+)-(1S, 2R, 4R)-4-(6-Chloro-5-formamido-2-isobutyramido-4-pyrimidinyl)-2-(hydroxymethyl)-1-cyclopentanol

(1R, 3S, 4R)-tert-Butyl N-(3-hydroxy-4-(hydroxymethyl)-1-cyclopentyl)carbamate (5.00 g, 21.6 mmol), 1N hydrochloric acid (44 mL), and dioxane (10 mL) were stirred at ambient temperature for two hours. This solution was evaporated to colorless oil (3.92g). This oil was refluxed with triethylamine (9.0 mL) and N-(4,6-dichloro-5-formamido-2-pyrimidyl) isobutyramide (EP 434450, June 26 1991) (5.99g, 21.6 mmol) in t-butyl alcohol (75 mL) for 1.0 hour. The cooled solution was treated with 1N sodium hydroxide (44 mL) and evaporated to a syrup which was chromatographed on silica gel. The title compound was eluted with MeOH:CHCl₃/1:4 as a tan solid foam (6.79g, 83%). Such a sample was slurried in diethyl ether to give off-white powder, m.p.: collapses at 105-108°C; mass spectrum (CI, CH₄) 372 (M + 1); ¹H-NMR (DMSO): δ 1.06 (d, J = 6.8 Hz, 6H), 1.22 (m, 1H), 1.80 (m, 3H), 2.19 (m, 1H), 2.90 (m, 1H), 3.35 (m, 2H), 3.92 (m, 1H), 4.57 (m, 3H), [7.11 (d, J = 7.8 Hz), 7.39 (d, J = 7.8 Hz), 1H]; [7.89 (d, J = 11.4 Hz), 8.16(s), 1H], [8.82(d, J = 11.4 Hz), 9.29(s), 1H], [10.17(s), 10.23(s), 1H], [α]_D²⁰₅₈₉ + 23.6°, [α]_D²⁰₅₇₈ + 24.9°, [α]_D²⁰₅₄₆ + 28.9°, [α]_D²⁰₄₃₆ + 53.4°, [α]_D²⁰₃₆₅ + 96.2° (c = 0.71, methanol).

Anal. Calcd. for C₁₅H₂₂N₅O₄Cl·0.45 H₂O·0.35 EtOH; C, 45.61; H, 6.36; N, 17.68; Cl, 8.95.

Found: C, 47.84; H, 6.19; N, 17.42; Cl, 9.02.

Example 21(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol

(1S, 2R, -4R)-4-(6-Chloro-5-formamido-2-isobutyramide-4-pyrimidinyl)-2-(hydroxymethyl)-1-cyclopentanol (6.25g, 16.8 mmol) was maintained at 55°C in 1N hydrochloric acid (85 mL) for 4 hours. Evaporation gave a dark oil which was dissolved in N,N-dimethylformamide (20 mL) and triethylorthoformate (85 mL). The resulting solution was stirred at ambient temperature for 16 hours. Volatiles were removed under vacuum and the residual oil stirred in 1N hydrochloric acid (100 mL) for 5 hours. The solution was neutralized with sodium hydroxide and evaporated to a brown syrup. Chromatography on silica gel with methanol:chloroform/ 15:85 gave title compound as a solid foam (3.9g). Crystallization from acetonitrile-methanol (1:1) gave title compound as white crystals (2.59g, 53%); m.p.

143-144°; mass spectrum (Cl, CH₄) 284 (M + 1); ¹H-NMR (DMSO): δ 1.67 (m, 1H), 2.01 (m, 2H), 2.17 (m, 1H), 2.33 (m, 1H), 3.45 (m, 1H), 3.52 (m, 1H), 4.09 (m, 1H), 4.65 (t, J = 5.1 Hz, 1H), 4.80 (d, J = 4.0 Hz, 1H), 4.91 (m, 1H), 6.88 (br s, 2H), 8.25 (s, 1H), [α]_D²⁰₅₈₉ + 17.5°, [α]_D²⁰₅₇₈ + 18.3°, [α]_D²⁰₅₄₆ + 20.5°, [α]_D²⁰₄₃₆ + 34.2°, [α]_D²⁰₃₆₅ + 49.4° (c = 0.67, methanol).

Anal. Calcd. for C₁₁H₁₄N₅O₂Cl·0.5 H₂O: C, 45.13; H, 5.16; N, 23.92; Cl, 12.11.

Found: C, 45.05; H, 5.02; N, 23.73; Cl, 12.13.

Example 22

(+)-(1S, 2R, 4R)-4-[2-Amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol

In the same manner as for the racemate, Example 18, title compound was isolated, after chromatography, as white solid foam (48% from 2.0 mmoles of (+)-(1S, 2R, 4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol); m.p.: collapses at 79-83°; mass spectrum (Cl, CH₄): 319 (M + 1); ¹H-NMR(DMSO-d₆) δ: 7.83 (s, 1, H-8), 5.79 (br s, 2, NH₂), 4.95-4.80 (m, 1, CHN), 4.75 (d, J = 4.0 Hz, 1, OH), 4.64 (t, J = 5.2 Hz, 1, CH₂OH), 4.05 (br m, 1, CHO), 3.60-3.35 (m, 2, CH₂O), 3.25-3.15 (m, overlapping s at 3.25, 4, CHNMe, CH₃), 2.35-2.20 (m, 1, CH), 2.20-2.0, (m, 1, $\frac{1}{2}$ CH₂), 2.0-1.85 (m, 2, methylene), 0.85-0.60 (m, 4, 2CH₂ of cyclopropyl); [α]_D²⁰₅₈₉ + 10.6°, [α]_D²⁰₅₇₈ + 10.8°, [α]_D²⁰₅₄₆ + 12.3°, [α]_D²⁰₄₃₆ + 20.6°, [α]_D²⁰₃₆₅ + 31.3° (c = 0.84, methanol).

Anal. Calcd. for C₁₅H₂₂N₆O₂·0.5 H₂O·0.04 EtOH; C, 55.02; H, 7.11; N, 25.53.

Found: C, 55.02; H, 7.06; N, 25.59.

Example 23

(+)-(1S, 2R, 4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol

(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol (425 mg, 1.5 mmol), cyclopropylamine (Aldrich, 1.4 mL), and ethanol (4 mL) were refluxed for 3 hours. To the cooled solution was added 1N sodium hydroxide (1.5 mL). The residual oil left on evaporation of volatiles under vacuum was chromatographed on silica gel. Title compound was eluted with methanol: ethyl acetate /15:85 as a white solid foam which solidified to white powder in methanol-acetonitrile (309 mg, 68%); m.p. 174-176°C; mass

spectrum (Cl, CH₄) 305 (M + 1); ¹H-NMR(DMSO-d₆) δ: 7.79 (s, 1, H-8); 7.25 (d, J = 2.9 Hz, 1, NH), 5.79 (s, 2, NH₂), 4.90-4.75 (m, 1, CH-N), 4.73 (d, J = 4.0 Hz, 1, OH), 4.63 (t, J = 5.3 Hz, 1, CHOH), 4.08-4.00 (m, 1, CHO), 3.58-3.38 (m, 2, CH₂O), 3.05-2.95 (m, 1, CH-NH), 2.35-2.20 (m, 1, CH), 2.18-2.0 (m, 1, $\frac{1}{2}$ CH₂), 2.0-1.9 (m, 2, methylene), 1.7 - 1.5 (m, 1, $\frac{1}{2}$ CH₂), 0.70-0.50 (m, 4, 2CH₂ of cyclopropyl); [α]₂₀⁵⁸⁹ + 7.72°, [α]₂₀⁵⁷⁸ + 7.87°, [α]₂₀⁵⁴⁶ + 8.77°, [α]₂₀⁴³⁶ + 14.4°, [α]₂₀³⁶⁵ + 20.1° (c = 0.66, methanol).

Anal. Calcd. for C₁₄H₂₀N₆O₂: C, 55.25; H, 6.62; N, 27.62.

Found: C, 55.21; H, 6.59; N, 27.54.

Example 24

(+)-(1S, 2R, 4R)-4-(2-Amino-1,6-dihydro-6-thioxo-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol

(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol. (1.70g, 6.00 mmol) and thiourea (456 mg, 6.00 mmol) were refluxed in water (15 mL) for 1.0 hour. The cooled solution was adjusted to pH5 with saturated aqueous sodium bicarbonate. The resulting precipitate was filtered, washed with water and dried to give title compound as white powder (1.20g, 71%); m.p. 290-291° dec; mass spectrum (Cl, CH₄) 282 (M + 1); ¹H-NMR (DMSO-d₆) δ: 11.90 (br s, 1, NH), 8.03 (s, 1, H-8), 6.78 (br s, 2, NH₂), 4.95 - 4.70 (m, overlapping d at 4.78, J = 2.7 Hz, total 2, CHN and OH), 4.7-4.6 (m, 1, CH₂OH), 4.1-4.0 (m, 1, CHOH), 3.6-3.4 (m, 2, CH₂O), 2.4-2.2 (m, 1, CH), 2.2 - 1.9 (m, 3, methylene), 1.7-1.5 (m, 1, $\frac{1}{2}$ CH₂); [α]₂₀⁵⁸⁹ + 6.43°, [α]₂₀⁵⁷⁸ + 6.71°, [α]₂₀⁵⁴⁶ + 7.43°, [α]₂₀⁴³⁶ + 8.43°, [α]₂₀³⁶⁵ + 8.43° (c = 0.70, 0.1N NaOH).

Anal. Calcd. for C₁₁H₁₅N₅SO₂: C, 46.96; H, 5.37; N, 24.90; S, 11.40.

Found: C, 46.83; H, 5.40; N, 24.88; S, 11.47.

Example 25

(+)-(1S, 2R, 4R)-4-[2-Amino-6-(1-pyrrolidinyl)-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol

(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol (426 mg 1.5 mmol), pyrrolidine (99%, Aldrich, 1.26 mL), and ethanol (8 mL) were refluxed for 20 minutes. To the cooled solution was added 1N sodium hydroxide (1.5 mL). Volatiles

were evaporated and the residue chromatographed on silica gel. Title compound was eluted with 12% methanol-chloroform as a white solid foam which solidified from 95% ethanol to white powder (324 mg, 64%); mp 114-117°; mass spectrum (CI, CH₄): 319 (M + 1); ¹H-NMR (DMSO-d₆) δ: 7.81 (s, 1, H-8), 5.76 (br s, 2, NH₂), 5.0-4.8 (m, 1, CHN), 4.76 (d, J = 4.1 Hz, 1, OH), 4.66 (t, J = 5.2 Hz, 1, CH₂OH), 4.15-4.0 (m, overlapping br m at 4.1-3.4 and m at 3.6-3.35, total 7, CHO, 2CH₂N and CH₂O), 2.4-2.2 (m, 1, $\frac{1}{2}$ CH₂), 2.2-1.8 (m, 7, methylenes), 1.7-1.5 (m, 1, $\frac{1}{2}$ CH₂); [α]_D²⁰₅₈₉ + 10.5°, [α]_D²⁰₅₇₈ + 11.0°, [α]_D²⁰₅₄₆ + 12.4°, [α]_D²⁰₄₃₆ + 19.5°, [α]_D²⁰₃₆₅ + 25.5° (c = 1.43, methanol).

Anal. Calcd. for C₁₅H₂₂N₆O₂·0.2H₂O·0.3 EtOH: C, 55.80; H, 7.26; N, 25.03.

Found, C, 56.01; H, 7.31; N, 24.82.

Example 26

(+)-(1S, 2R, 4R)-4-[6-(allylthio)-2-amino-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol

(+)-(1S, 2R, 4R)-4-(2-Amino-1,6-dihydro-6-thioxo-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol (351 mg, 1.25 mmol) and 1N sodium hydroxide (1.25 mL) were stirred with allyl chloride (0.15 mL) for 5 hours. The solution was neutralized with hydrochloric acid and volatiles evaporated. The residue was chromatographed on silica gel. Title compound was eluted with 12% methanol-chloroform as a white solid foam which solidified to white powder from acetonitrile (240 mg, 60%); m.p. 133-134°; mass spectrum (CI, CH₄): 322 (M + 1); ¹H-NMR (DMSO d₆) δ: 8.07 (s, 1, H8), 6.51 (br s, 2, NH₂), 6.10-5.85 (m, 1, CH=), 5.45-5.30 (m, 1, $\frac{1}{2}$ CH₂=), 5.15-5.05 (m, 1, $\frac{1}{2}$ CH₂=), 5.0-4.8 (m, 1, CHN), 4.79 (d, J = 4.1 Hz, 1, OH), 4.66 (t, J = 5.2 Hz, 1, CH₂OH), 4.15-4.0 (m, 1, CHO), 3.98 (d, J = 6.9 Hz, 2, CH₂S), 3.6-3.4 (m, 2, CH₂O), 2.4-1.9 (m, 4, CH + methylenes), 1.75-1.55 (m, 1, $\frac{1}{2}$ CH₂); [α]_D²⁰₅₈₉ + 9.30°, [α]_D²⁰₅₇₈ + 9.68°, [α]_D²⁰₅₄₆ + 11.1°, [α]_D²⁰₄₃₆ + 18.6°, [α]_D²⁰₃₆₅ + 25.4° (c = 0.79, methanol).

Anal. Calcd. for C₁₄H₁₉N₅O₂S: C, 52.32; H, 5.96; N, 21.79; S, 9.98.

Found: C, 25.35; H, 5.94; N, 21.82; S, 9.88.

Example 27(+)-(1S, 2R, 4R)-4[2-amino-6-(1-azetidinyl)-9H-purin-9-yl]-2-(hydroxymethyl)-1-cyclopentanol

(+)-(1S, 2R, 4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol (340 mg, 1.20 mmol) and azetidine (98%, Aldrich, 1.0 mL) and methanol (6 mL) were maintained at 60°C in a sealed tube for 18 hours. To the cooled solution was added 1N sodium hydroxide (1.2 mL). Volatiles were evaporated and the residue chromatographed on silica gel. Title compound was eluted with methanol: ethyl acetate / 15:85 as a white foam which solidified to white powder from methanol-acetonitrile (333 mg, 91%), mp 194-195°; mass spectrum (CI, CH₄) 305 (M + 1); ¹H-NMR (DMSO-d₆) δ: 7.81 (s, 1, H8), 5.88 (br s, 2, NH₂), 4.95-4.80 (m, 1, CH-N), 4.76 (d, J = 3.9 Hz, 1, OH), 4.66 (t, J = 5.0 Hz, 1, CH₂-OH), 4.4-4.15 (br m, 4, 2CH₂N), 4.10-4.0 (m, 1, CHO), 3.6-3.4 (m, 2, CH₂O), 2.5-1.9 (m, 6, methylene), 1.75-1.5 (m, 1, $\frac{1}{2}$ CH₂); [α]_D²⁰₅₈₉ + 10.1°, [α]_D²⁰₅₇₈ + 10.7°, [α]_D²⁰₅₄₀ + 11.9°, [α]_D²⁰₄₃₆ + 18.3°, [α]_D²⁰₃₆₅ + 25.2° (c = 0.812, methanol).

Anal. Calcd. for C₁₄H₂₀N₆O₂: C, 55.25; H, 6.62; N, 27.62.

Found: C, 55.31; H, 6.63; N, 27.71.

Example 28(+)-(1S, 2R, 4R)-4-(2-Amino-6-(cyclopentyloxy)-9H-purin-9-yl)-2-(hydroxymethyl)-1-cyclopentanol

Sodium hydride (60% oil dispersion, 113 mg) was added to cyclopentanol (7 mL). To the resulting solution, after effervescence had ceased, was added (+)-(1S-2R-4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)cyclopentanol (400 mg, 1.4 mmol). The solution was maintained at 85° for 40 minutes, cooled to room temperature, and neutralized with 1N hydrochloric acid. Volatiles were removed and the residue chromatographed on silica gel. Title compound was eluted with methanol: chloroform / 15:85 as a white solid foam which solidified from acetonitrile: methanol / 20:1 as a white powder (223 mg, 48%), m.p. 181-182°; mass spectrum (CI, CH₄): 334(M + 1); ¹H-NMR (DMSO-d₆) δ: 7.97 (s, 1, H8), 6.32 (br s, 2, NH₂), 5.60 (m, 1, CHO of cyclopentyl) 5.0-4.8 (m, 1, CHN), 4.78 (d, J = 4.1 Hz, 1, OH), 4.66 (t, J = 5.1 Hz, 1, CH₂OH), 4.1 (m, 1, CHOH), 3.6-3.4 (m, 2, CH₂O), 2.4-1.9 (m, 6

methylene), 1.9-1.5 (m, 7, methylene); $[\alpha]^{20}_{589} + 9.34^\circ$, $[\alpha]^{20}_{578} + 9.85^\circ$, $[\alpha]^{20}_{546} + 11.1^\circ$, $[\alpha]^{20}_{430} + 18.2^\circ$, $[\alpha]^{20}_{365} + 26.6^\circ$ ($c = 0.782$, methanol).

Anal. Calcd. for $C_{16}H_{23}N_5O_3$: C, 57.65; H, 6.95; N, 21.01.

Found: C, 57.74; H, 6.94; N, 20.91.

Example 29

(1S,4R)-[2-(2-Amino-6-chloro-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol

A solution of (-)-2-azabicyclo[2.2.1]hept-5-en-3-one (Enzymatix lot #LN1253, 30.0g, 275mmol) in anhydrous tetrahydrofuran (150 mL) in a 2L 3-neck round bottom flask under nitrogen was equipped with a thermometer and mechanical stirrer, then warmed to 35°C (most of solid dissolved). Meanwhile, a solution of methanesulfonic acid (28.0g, 291mmol) and water (5.35g, 297mmol) in tetrahydrofuran (50 mL) was prepared (caution-mixing is highly exothermic). This solution was slowly added dropwise via an addition funnel to the 2L flask over 10 min. Initially the solution became turbid, and by the end of the addition some solid had appeared on the side of the flask. The mixture was heated to gentle reflux for 3h (internal temperature 62-65°C), then cooled (-15°C). An air-dried sample of the white solid had $^1\text{H-NMR}$ identical with the sample of (-)-(1S, 4R)-4-amino-2-cyclopentene-1-carboxylic acid methanesulfonate described in Example 1. A solution of 1.0 N lithium aluminum hydride in tetrahydrofuran (Aldrich, 525mL, 525 mmol) was added dropwise to the mixture (slowly at first, more rapidly later) so that pot temperature remained below 0°C. After addition was complete (required approx. 35 min) the mixture was slowly warmed to 22°C and stirred at room temperature for 17h, then refluxed for 5h and cooled to ambient. Sodium fluoride (150g, 3.57 mol) was added, stirring was continued for 30 min, then the mixture was cooled on an ice bath (5°C). Water (38g, 2.1mol) was added dropwise so that pot temperature remained below 20°C (over 30 min), then the mixture was stirred at room temperature for 20 min and filtered. The filter cake was washed with tetrahydrofuran/methanol (5:2), and the filtrate was set aside. The filter cake was taken up in tetrahydrofuran/methanol (5:2, 700 mL), stirred for 15 min, and filtered. This extraction was repeated and the three filtrates were combined and cooled (0°C), then refiltered. A 1 mL aliquot of this solution was concentrated to give (-)-(1S, 4R)-4-amino-2-cyclopentene-1-methanol as a colorless oil with identical analysis to the sample described in Example 2 and 3. The remainder of the solution was partially concentrated *in vacuo*, diluted with 1-butanol (500 mL), further concentrated to remove tetrahydrofuran and methanol, and transferred to a 1L 3-neck flask under nitrogen equipped with a thermometer and reflux condenser.

Triethylamine (125 mL, 900 mmol) and 2-amino-4,6-dichloropyrimidine (47.0 g, 286 mmol) were added, and the mixture was refluxed for 4 h (internal temperature 107-108°C). The reaction solution was partially concentrated *in vacuo* and treated with 5N sodium hydroxide (60 mL, 300 mmol). The solution was concentrated *in vacuo*, diluted with toluene (100 mL), and further concentrated in order to remove the remaining triethylamine. The residual oil was taken up in chloroform (500 mL) and methanol (100 mL), then the mixture was filtered. The filter cake was washed with methanol/chloroform (1:9), then the filtrate was concentrated *in vacuo* and the residual oil dissolved in chloroform and loaded onto a column of silica gel containing 300 g of silica. The column was initially eluted with 3% ethanol/chloroform, then with 8% ethanol/chloroform to afford pure fractions of the subject compound; these were concentrated *in vacuo* to constant weight to afford (1S,4R)-[2-(2-amino-6-chloro-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol as a pale tan gum (53.1 g, 75%); mp 73-75°C as a pale tan solid hydrate (methanol/water). ¹H-NMR (DMSO-d₆): 7.00-7.10(br s, 1H); 6.35-6.45(br s, 2H); 5.87(m, 1H); 5.73(s, 1H); 5.71(m, 1H); 4.90-5.05(br s, 1H); 4.64(t, 1H, J = 5 Hz); 3.36(m, 2H); 2.60-2.75(m, 1H); 2.30-2.40(m, 1H); 1.20-1.30(m, 1H). Ms (CI): m/z 241 (m + H⁺, 100). [α]_D²⁰₅₈₉ -27.3° (c = 0.54, methanol).

Anal. Calcd for C₁₀H₁₃ClN₄O·H₂O: C, 46.43; H, 5.84; N, 21.66. Found: C, 46.49; H, 5.81; N, 21.79.

Example 30

(1S,4R)-4-((2-Amino-6-chloro-5-((4-chlorophenyl)azo)-4-pyrimidinyl)amino)-2-cyclopentene-1-methanol

An ice cooled (5°C) solution of 4-chloroaniline (5.74 g, 45 mmol) in a mixture of water (50 mL) and concentrated hydrochloric acid (13.6 mL) was treated dropwise with a cooled (5°C) solution of sodium nitrite (3.11 g, 45 mmol) in water (25 mL) at a rate to keep the pot temperature below 10°C. This solution was placed in a dropping funnel and added dropwise to a mechanically stirred, cooled (5°C) solution of sodium acetate trihydrate (49 g, 360 mmol) and (1S,4R)-2-(2-amino-6-chloro-4-pyrimidinyl)amino-2-cyclopentene-1-methanol hydrate (9.99 g, 40 mmol) in water/acetic acid (1:1, 100 mL) at a rate to keep the pot temperature below 10°C. The mixture was warmed and stirred at room temperature for 18 h, then filtered. The filter cake was washed with water, air dried, and triturated from acetonitrile to afford 14.26 g (91%) of the title compound as a hydrate (1:0.75); mp 218-20°C (dec). ¹H NMR (DMSO-d₆): 10.25(d, 1H, J = 7 Hz); 7.70(d, 2H, J = 9 Hz); 7.55(d, 2H, J = 9 Hz); 5.94(m, 1H); 5.83(m, 1H); 5.20-5.30(m, 1H); 3.35-3.50(m, 2H); 2.70-2.80(m, 1H); 2.40-

2.50(m,1H); 1.40-1.55 (m,1H). Ms (CI): m/z 283 (m-C5 ring, 60); 343 (m-Cl, 40); 379 (m + H⁺, 100). $[\alpha]^{20}_{589} + 26.8^{\circ}$ (c = 0.51, methanol).

Anal. Calcd for C₁₆H₁₆Cl₂N₆O·0.75H₂O: C, 48.93; H, 4.49; N, 21.40. Found: C, 49.02; H, 4.51; N, 21.42.

Example 31

(1S,4R)-4-(2,5-Diamino-6-chloro-4-pyrimidinyl)amino)-2-cyclopenten-1-methanol

A suspension of (1S,4R)-4-((2-amino-6-chloro-5-((4-chlorophenyl)azo)-4-pyrimidinyl)-amino)-2-cyclopentene-1-methanol hydrate (0.76g, 2.0 mmol) in methanol/acetic acid/water (6:2:1, 9mL) was treated in portions over 10 min with zinc powder (1.0g, 15.3 mmol) so that the pot temperature remained below 35°C. The mixture was stirred at room temperature for 1h and at 40°C for 1h, then concentrated *in vacuo* with addition of toluene to remove acetic acid and water. The residue was taken up in 5% isopropanol-chloroform and loaded onto a silica gel column, which was eluted with 8% isopropanol-chloroform, then with 15% isopropanol-chloroform to afford pure fractions of the subject compound, which were combined and concentrated *in vacuo* to afford (1S,4R)-4-(2,5-diamino-6-chloro-4-pyrimidinyl)amino)-2-cyclopenten-1-methanol as a pink-tan solid (0.39g, 76%); mp 159.5-161.0°C. ¹H NMR (DMSO-d₆): 6.41(d,1H,J = 7Hz); 5.85-5.95(m,1H); 5.70-5.80(m,1H); 5.62(br s,2H); 5.00-5.15(m,1H); 4.67(t,1H,J = 5Hz); 3.96(br s,2H); 3.35-3.45 m,2H); 2.60-2.80(m,1H); 2.30-2.50(m,1H); 1.20-1.40(m,1H). Ms (CI): m/z 160 (m-C5 ring, 90); 220 (m-Cl, 40); 255 (m + H⁺, 100). $[\alpha]^{20}_{589} + 0.37^{\circ}$, $[\alpha]^{20}_{436} -9.41^{\circ}$ (c = 0.54, methanol).

Anal. Calcd for C₁₀H₁₄ClN₅O: C, 46.97; H, 5.52; N, 27.39. Found: C, 47.03; H, 5.54; N, 27.45.

Example 32

(1S,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol

A suspension of (1S,4R)-4-((2-Amino-6-chloro-5-((4-chlorophenyl)azo)-4-pyrimidinyl)amino)-2-cyclopentene-1-methanol hydrate (1.96g, 5 mmol) in tetrahydrofuran (15 mL) was treated with acetic acid/water (1:1, 5 mL), then with zinc dust (1.63g, 25 mmol) in portions so as to keep the pot temperature below 35°C. The deep yellow color faded after 10 min, and after an additional 50 min the solution was filtered to remove precipitated zinc salts. The filter

cake was rinsed with tetrahydrofuran and the filtrate was refiltered to remove additional zinc salts, then concentrated *in vacuo* with addition of toluene to facilitate removal of water and acetic acid. The residue was rinsed with toluene/hexane to separate some of the 4-chloroaniline byproduct, taken up in triethyl orthoformate (40 mL), cooled on an ice bath (5°C), and treated dropwise with concentrated hydrochloric acid (1.9 mL). The mixture was stirred at 5°C for 5h (tan suspension soon formed), slowly warmed to room temperature, and stirred for an additional 18h, then cooled on an ice bath and filtered. The filter cake was rinsed with ether (save filtrate), and this solid was taken up in water (30 mL), filtered, and the solids washed with water. The aqueous filtrate was basified with sodium carbonate to pH-9, then extracted with 5% isopropanol-chloroform (3X25 mL). The combined extracts were dried (Na₂SO₄) and concentrated *in vacuo* to a residual tan foam (0.85g). The organic filtrate from above was concentrated *in vacuo* and the residue taken up in 1N hydrochloric acid (30 mL), stirred for 1h, filtered, and the filtrate adjusted to pH-6 with 5 N sodium hydroxide (6 mL), then basified with sodium carbonate. This aqueous suspension was extracted with 5% isopropanol-chloroform (3X25 mL), and the combined organic extracts were dried (Na₂SO₄) and concentrated *in vacuo* to a tan foam (0.55g). The two batches were combined, dissolved in warm chloroform, and loaded onto a silica gel column, which was eluted with 7% methanol-chloroform to afford pure fractions containing the subject compound. These were concentrated *in vacuo* and the residual foam crystallized from ethyl acetate (2 crops) to afford 0.86g (65%) of the title compound as a pale tan solid; mp 160-162°C. ¹H-NMR (DMSO-d₆) δ : 8.04(s,1H); 6.91(s,2H); 6.15(m,1H); 5.90 (m,1H); 5.45 (m,1H); 4.73 (t,1H,J = 5Hz); 3.45(t,2H,J = 5Hz); 2.80-2.95(m,1H); 2.55-2.70(m,1H); 1.60-1.70(m,1H). Ms(Cl): m/z 170 (m-C5 ring, 100); 230 (m-Cl, 50); 266 (m + H⁺, 100). [α]_D²⁰₅₈₉ -104°, [α]_D²⁰₄₃₆ -267° (c = 0.29, methanol).

Anal. Calcd for C₁₁H₁₂ClN₅O: C, 49.73; H, 4.55; N, 26.36. Found: C, 49.89; H, 4.61; N, 26.25.

Example 33

(-)-(1S, 4R)-4-[2-Amino-6-(cyclopropylmethylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol

(1S, 4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol (274 mg, 1.00 mmol), N-cyclopropyl-N-methylamine (0.71 g, 10 mmol) and absolute ethanol were refluxed for 5.0 hours. Volatiles were evaporated and the residue chromatographed on silica gel. Title compound was eluted with 10% methanol-chloroform as a colorless glass. Evaporation of

an ethanol solution gave title compound as a colorless solid foam (293 mg, 98%). $^1\text{H-NMR}$ (DMSO-d_6) δ : 0.56 and 0.63 (2m, 4, 2-cyclopropyl CH_2), 1.56 and 2.60 (2m, 2, cyclopentenyl CH_2), 2.85 (m, 1, H-4'), 3.02 (m, 1, cyclopropyl CHNH), 3.43 (m, 2, CH_2OH), 4.71 (t, 1, CH_2OH); 5.40 (m, 1, H-1'), 5.85-5.70 (m overlapping s at 5.77, 3, NH_2 and $=\text{CH}$), 6.09 (m, 1, $=\text{CH}$), 7.23 (d, 1, NHCH), 7.58 (s, 1, purine H-8); ms (CI) 287 (m + 1). $[\alpha]^{20}_{589} -59.7^\circ$, $[\alpha]^{20}_{436} -128^\circ$ (c = 0.15, methanol).

Anal. Calcd. for $\text{C}_{14}\text{H}_{18}\text{N}_6\text{O} \cdot 0.15 \text{ EtOH} \cdot 0.05 \text{ H}_2\text{O}$: C, 58.39; H, 6.51; N, 28.57. Found: C, 58.11; H, 6.84; N, 28.92.

Example 34


(+)-(1R, 4S)-4-Amino-2-cyclopentene-1-methanol

A mixture of (-)-(1S, 4R)-4-amino-2-cyclopentene-1-carboxylic acid (Chiros Ltd., Cambridge, England; 40.00 g, 0.315 mole) in dry tetrahydrofuran (300 mL) was stirred in an ice bath while 1 M lithium aluminum hydride in tetrahydrofuran (Aldrich, 485 mL) was added over 1.5 hours. The temperature during this addition was not allowed to exceed 0°C . The mixture was brought to ambient temperature and then to reflux over one hour and maintained at reflux for 2.5 hours. The mixture was allowed to cool to ambient temperature and sodium fluoride (89.6 g) was added and stirring continued for an additional 0.5 hour. The mixture was cooled (ice bath) and water (23 mL) added slowly. Stirring was continued for an additional 0.5 hour. The precipitate was filtered and extracted with 40% methanol-tetrahydrofuran (2x300 mL). The filtrate-wash was concentrated in vacuo to a colorless oil which darkened rapidly in air and light. Such a sample was dried at ambient temperature / 0.2 mm Hg to a pale yellow oil; $^1\text{H-NMR}$ (DMSO-d_6) identical to that of the enantiomer described in Example 1, d: 5.67 (m, 2, $\text{CH}=\text{CH}$), 3.8-3.7 (m, 1, CHN), 3.32 (d, J = 6.0 Hz, overlapped by broad D_2O -exchangeable peak centered at 3.18, CH_2O , OH, NH_2 and H_2O in solvent), 2.68-2.56 (m, 1, H-1), 2.28-2.18 (m, 1, $1/2 \text{ CH}_2$), 1.08-0.98 (m, 1, $1/2 \text{ CH}_2$); mass spectrum (CI): 114 (M + 1); $[\alpha]^{20}_{589} + 55.0^\circ$, $[\alpha]^{20}_{578} + 58.3^\circ$, $[\alpha]^{20}_{546} + 67.4^\circ$, $[\alpha]^{20}_{436} + 119^\circ$ (c = 0.242, methanol).

Anal. Calcd. for $\text{C}_6\text{H}_{11}\text{NO} \cdot 0.31 \text{ H}_2\text{O}$: C, 60.69; H, 9.86; N, 11.80. Found: C, 61.12; H, 9.79; N, 11.38.

CLAIMS

1. A compound of formula (I):



(I)

wherein R^1 represents

hydrogen;

C_{3-8} alkenyloxy; C_{3-8} cycloalkoxy; C_{4-8} cycloalkenyloxy; aryloxy or arylalkoxy in which the aryl may be substituted with one or more C_{1-4} alkyl, halogen, hydroxy, C_{1-4} alkoxy, amino or nitro;


C_{3-6} alkenylthio; C_{3-6} cycloalkylthio; C_{4-8} cycloalkenylthio; arylthio or arylalkylthio in which the aryl may be substituted with one or more C_{1-4} alkyl, halogen, hydroxy, C_{1-4} alkoxy, amino or nitro;

an amino group, $-NR^2R^3$, in which R^2 and R^3 may be the same or different and are independently selected from hydrogen; C_{1-8} alkyl; C_{1-6} alkoxy; C_{1-6} hydroxyalkyl; C_{1-6} alkoxyalkyl; C_{3-7} cycloalkyl in which the cycloalkyl may be substituted by one or more C_{1-6} alkyl or hydroxy; aryl or aralkyl in which the aryl may be substituted with one or more C_{1-4} alkyl, halogen, hydroxy, C_{1-4} alkoxy, amino or nitro; C_{3-6} alkenyl; or R^2 and R^3 together form a 4- to 8-membered ring; provided that R^2 and R^3 cannot both be hydrogen or both be C_{1-8} alkyl;

4-morpholinyl, 1-piperazinyl or 1-pyrrollyl;


or a pharmaceutically acceptable derivative thereof.

2. A compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof for use in medical therapy.
3. A compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof for use in the treatment or prophylaxis of hepadnaviral infections or herpes viral infections.
4. Use of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment or prophylaxis of hepadnaviral infections or herpes viral infections.
5. A method for the treatment or prophylaxis of a hepadnaviral infection or a herpes viral infection in a subject which comprises treating the subject with an effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof.
6. Pharmaceutical formulations comprising a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefor.
7. A process for the preparation of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable derivative thereof alone or in combination with its corresponding enantiomer which comprises treating a compound of formula (Ia) either alone or in combination with its corresponding enantiomer:




(wherein Z represents a precursor group for the group R^1 defined in formula (I)) under conditions or with a reagent serving to convert the said Z group to the desired R^1 group).

8. A process for the preparation of (-)-(1S,4R)-4-amino-2-cyclopentene-1-methanol of formula (VIb) below, its mirror image enantiomer or a mixture of such enantiomers:-




which comprises reducing (-)-(2S,4R)-4-amino-2-cyclopentene-1-carboxylic acid of formula (VIII) below or a salt thereof, its mirror image enantiomer or a mixture of such enantiomers:




(VIII)

9. A process as claimed in claim 8 where in the compound of formula (VIII) its mirror image enantiomer or a mixture of such enantiomers is in the form of a base salt or an acid addition of formula (VIIIa) or (VIIIb), respectively:- its mirror image enantiomer or a mixture of such enantiomers.



(VIIIa)




(VIIIb)

wherein W^+ represents a cation and X^- represents an anion.

10. A process as claimed in claim 9 wherein the compound of formula (VIII), its mirror image enantiomer or a mixture of such enantiomers is employed in the form of a compound of formula (VIIIb), its mirror image enantiomer or a mixture of such enantiomers wherein X^- represents the anion of an organic sulphonic acid.
11. A process as claimed in any of claims 8 to 10 wherein the reduction is effected using an aluminium hydride.
12. A process for the preparation of a compound of formula (VIIIb) (as defined in claim 9), its mirror image enantiomer or a mixture


of such enantiomers which comprises reacting (-)-2-azabicyclo[2.2.1]hept-5-en-3-one of formula (IX), its mirror image enantiomer or a mixture of such enantiomers:-



(IX)

with one or more equivalents of an acid and one or more equivalents of water.

13. A process as claimed in claim 12 wherein the said acid has a pKa of less than two.
14. A process for the preparation of a compound of formula (VIIIb) as defined in claim 9 wherein X^- represents the anion of a C_{1-6} alkyl- or aryl-sulphonic acid its mirror image enantiomer or a mixture of such enantiomers which comprises subjecting to oxidative hydrolysis a compound of formula



(X)

wherein R^7 is C_{1-6} alkyl or aryl, its mirror image enantiomer or a mixture of such enantiomers.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 473/00, C07C 217/52 C07D 221/22, A61K 31/52, C07C 229/48	A3	(11) International Publication Number: WO 93/17020 (43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/GB93/00378 (22) International Filing Date: 24 February 1993 (24.02.93) (30) Priority data: 9204015.3 25 February 1992 (25.02.92) GB (71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : DALUGE, Susan, Mary [US/US]; 297 Azalea Drive, Chapel Hill, NC 27514 (US). LIVINGSTON, Douglas, Alan [US/US]; LaJolla Pharmaceutical Co., 6455 Nancy Ridge Drive, San Diego, CA 92121 (US).		(74) Agent: GARRETT, Michael; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 17 March 1994 (17.03.94)
(54) Title: THERAPEUTIC NUCLEOSIDES (57) Abstract The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain viral infections.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No

PC1/GB 93/00378

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D473/00 C07C217/52 C07D221/22 A61K31/52 C07C229/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 434 450 (THE WELLCOME FOUNDATION) 26 June 1991 *Page 16, example 20* *Page 31, claims 23-25* ---	1-12
A	EP,A,0 236 935 (TAKEDA) 16 September 1987 see page 1 *Page 8, example 5(1)* ---	1-6
A	EP,A,0 278 501 (TAKEDA) 17 August 1988 *Page 14, example 10* *Page 18, example 21* see claims ---	1-6
A	US,A,4 543 255 (Y. FULMER SHEALY) 24 September 1985 cited in the application *Document* ---	1-6

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

12 November 1993

Date of mailing of the international search report

- 9. 02. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

LUYTEN, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 93/00378

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 219 838 (TAKEDA) 29 April 1987 cited in the application *Document* ---	1-6
A	WO,A,90 06671 (PALESE PETER) 28 June 1990 cited in the application *Document* ---	1-6
A	WO,A,91 13549 (VIRACHEM) 19 September 1991 cited in the application *Document* ---	1-6
A	JOURNAL OF MEDICINAL CHEMISTRY vol. 30, no. 4 , April 1987 , WASHINGTON pages 746 - 749 JOHN A. SECRIST ET. AL. cited in the application ---	1-6
A	JOURNAL OF MEDICAL CHEMISTRY vol. 27, no. 11 , November 1984 , WASHINGTON pages 1416 - 1421 Y. FULMER SHEALY ET. AL. cited in the application ---	1-6
A	PROC NATL. ACAD. SCI. USA vol. 86 , November 1989 , WASHINGTON pages 8541 - 8544 PETER M. PRICE ET. AL. cited in the application ---	1-6
A	EP,A,0 424 064 (ENZYMATIX LTD) 24 April 1991 *Document* ---	12
A	ROYAL SOCIETY OF CHEMISTRY. PERKIN TRANSACTIONS 1. vol. 3 , March 1991 , CAMBRIDGE pages 656 - 657 CHRIS EVANS ET.AL. -----	12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/00378

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 5 and 6 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

For further information please see Form PCT/ISA/206 mailed on the 14/06/93

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 93/00378

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0434450	26-06-91	AU-B- 633672 AU-A- 6841990 CN-A- 1054981 US-A- 5206435	04-02-93 27-06-91 02-10-91 27-04-93
EP-A-0236935	16-09-87	AU-B- 596400 AU-A- 6972187 US-A- 4968674 JP-A- 63010787 SU-A- 1561826	03-05-90 10-09-87 06-11-90 18-01-88 30-04-90
EP-A-0278501	17-08-88	AU-A- 1164588 JP-A- 2000188	18-08-88 05-01-90
US-A-4543255	24-09-85	NONE	
EP-A-0219838	29-04-87	JP-A- 62096473 AU-A- 6868187 JP-A- 62174097	02-05-87 18-02-88 30-07-87
WO-A-9006671	28-06-90	AU-A- 4829190 CA-A- 2005192 EP-A- 0452360	10-07-90 12-06-90 23-10-91
WO-A-9113549	19-09-91	EP-A- 0471057 JP-T- 4505768	19-02-92 08-10-92
EP-A-0424064	24-04-91	JP-A- 3218380	25-09-91